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ABSTRACT 
HEATHER ANNE BOGER. Dual-Hit Hypothesis for Dopamine Neurodegeneration and 
Motor Dysfunction. (Under the direction of DR. ANN-CHARLOTfE GRANHOLM). 
Glial cell line-derived neurotrophic factor (GDNF) is a trophic factor for peripheral 
organs, spinal cord, and midbrain dopamine (DA) neurons. Studies have shown that 
GDNF levels decrease in the substantia nigra (SN) and striatum during normal aging and 
in patients with Parkinson's disease. Furthermore, exogenous GDNF infusion protects 
DA neurons against InjUry induced by 6-hydroxydopamine, MPTP, and 
methamphetamine (METR). A heterozygous mouse model was created to assess whether 
a chronic reduction in this neurotrophic factor impacts motor function and the 
nigrostriata1 DA system during the aging process. In this dissertation, two models of 
dopaminergic loss and motor dysfunction were characterized. First, a partial loss of 
GDNF demonstrated a slow, progressive loss of SN DAergic neurons as well as motor 
dysfunction with aging. Secondly, a possible model for a dual-hit hypothesis for 
dopamine neurodegeneration was described. In this model, mice with a partial loss of 
GDNF displayed an increase vulnerability to the neurotoxic effects of :METR. To 
determine if the damage caused by these two factors was primarily by inflammatory 
processes, minocycline, a second-derivative tetracycline with anti-inflammatory and 
neuroprotective properties, was administered. Treatment with minocycline was able to 
reduce substantia nigra microglial activation and phosphorylated p38 MAPK in all 
groups. Although minocycline treatment was able to partially restore the lower levels of 
tyrosine hydroxylase seen in GDNpl- mice, the antibiotic was unable to reverse the 
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damage associated with METH treatment. Thus, increased age-related vulnerability of 
the DA system is seen when a genetic predisposition (GDNF depletion) is combined with 
a post-natal neurotoxic exposure (METH binge). This dual-hit model may be useful for 




Substantia nigra dopamine neurons and motor function 
Dopamine (DA) is one of the most intensively studied neurotransmitters in the 
brain due to its involvement in several mental and neurological disorders. Midbrain 
DAergic neurons constitute the major source of DA in the mammalian central nervous 
system. The most prominent DAergic cell group resides in the ventral part of the 
mesencephalon, which contains approximately 90% of DAergic cells. The mesencephalic 
DAergic system was first mapped By Dahlstrom and Fuxe (1964) using fluorescence 
histochemistry and was subdivided into several nominal systems. These include the 
nigrostriatal, mesoslimbic, mesocortical, tuberoinfundibular, and tuberohypophyseal DA 
systems (Figure 1-1). 
The DA system focused on in this dissertation is the nigrostriatal system, that 
originates in the pars compacta of the substantia nigra (SNpc) and extends its fibers into 
the caudate-putamen (also known as the dorsal striatum). The nigrostriatal pathway plays 
an essential role in the control of voluntary movement and was demonstrated to be 
involved in the pathogenesis of Parkinson's disease (PD) by Arvid Carlsson for which he 
received the 2000 Nobel Prize for medicine (Benes, 2001; DeCamilli and Carew, 2000). 
Although DAergic neurons make up less than 1 % of the total number of brain neurons, 
they play an important role in regulating several aspects of basic brain function. They are 
necessary for tasks specific to the brain regions that they innervate including motor 
behavior, motivation and working memory (Chinta and Anderson, 2005; Schultz, 1997; 
Ljungberg et aI., 1992; Schultz, 1993). 
DA is synthesized in the presynaptic terminal by several metabolic pathways 
(Figure 1-2). First tyrosine in the cell is converted to L-dihydroxyphenylalanine (L-
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DOPA) by the enzyme, tyrosine hydroxylase (TH). L-DOPA is converted into DA by the 
enzyme, aromatic amino acid decarboxylase (AADC). When stimulated, DA is released 
into the synapse and the signal is propagated through DA receptors, and is then either 
taken back up into the presynaptic tenninal by dopamine transporters (DAT) or degraded 
by monoamine oxidase-A (MAO-A) into dihydrophenylacetic acid (DOPAC) and by 
MAO-B into homovanillic acid (HV A) or is degraded extracellularly by catechol-O-
methyltransferase (COMT) to 3-methoxytyramine and then converted to HV A by MAO-
B (Bannon and Roth, 1983; Bjorklund and Lindvall, 1984; Grace, 2002). Dopamine 
receptors, which are G-coupled protein receptors, can be divided into two groups: Dt-like 
receptors (D}, D5) and D2-like receptors (D2, D3, D4) (Missale et aI., 1998; Tang et aI., 
1994; Seeman et aI., 1994). Dt-like receptors, located postsynaptically in the striatum, 
nucleus accumbens, and substantia nigra (SN) mediate the dopamine-stimulated increase 
of adenylate cyclase activity, thereby increasing cAMP formation and the activation of 
cAMP-dependent protein kinase (PKA) , leading to the phosphorylation/activation of 
dopamine- and cyclic AMP-regulated phosphoprotein with molecular weight 32 kDa 
(DARPP-32) (Hemmings et aI., 1984; Greengard et aI., 1999; Neve et aI., 2004). Once 
DARPP-32 is activated, protein phosphatase 1 is inhibited and the phosphorylated state 
of phosphoproteins involved in various physiological processes is increased (Fienberg et 
aI., 1998). Conversely, D2 type receptors, when located postsynaptically in the striatum 
and nucleus accumbens exert an opposite influence on adenylate cyclase activity 
(Meador-Woodruff, 1994; Missale et aI., 1998). Dopamine D2 receptors are also 
classified as autoreceptors and ~ when located on the nerve terminal inhibit dopamine 
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synthesis and release (Chiodo, 1995). For an overview of dopamine signal transduction, 
see Figure 1-2. 
Aging and motor dysfunction 
The aged brain undergoes a series of subtle but progressive alterations which 
eventually lead to altered neuronal function and, ultimately, altered behavior of the 
individual. Together with an age-related decline in cognitive performance, it has also 
been found that motor function undergoes a steady and progressive decline in all aged 
humans (see ego Barbeau, 1973; Kokmen et aI., 1977; Richards et aI., 1993; Newman et 
aI., 1985; Volkow et aI., 1998; Kluger et aI., 1997). It has been shown in a clinical study 
(Bennett et aI., 1996) that the prevalence of extrapyramidal problems, or so called 
parkinsonism (two or more symptoms related to tremor, rigidity, gait disturbance, and 
bradykinesia), increases with age. In a recent study, approximately 15% between 65 to 
74 years of age, 30% between 75 to 84, and over 50% of people over 85 were classified 
as having parkinsonism (Bennett et aI., 1996). Recent studies using PET imaging indicate 
an age-related decline in the type 2 vesicular monoamine transporter (VMAT2) in normal 
individuals (0.77% per year). Individuals with PD had decreases in VMAT2 binding 
beyond alterations seen with normal aging (more than 60% decline in the putamen; see 
Frey et aI., 1996). These findings suggest that normal aging results in a slow but 
progressi ve loss of SN neurons ("age-related parkinsonism"), while PD gives rise to a 
rapidly evolving and more dramatic loss of these neurons. However, factors that may 
exacerbate this process and lead to either idiopathic PD or non-PD-related motor 
impairment during aging have not been fully elucidated. 
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The loss of DA neurons found in animal models of aging is comparable to 
findings in aged human brains. For example, Cass and collaborators (2002) reported a 
marked increase in the response to neurotoxins in aged substantia nigra DA neurons, and 
DA receptor binding (D2 receptors) is decreased in the brain of aged mice (Ossowska et 
aI., 2001). Other investigators have found a significant decline in both TH and DAT in 
the SN region of aged rodents (Himi et aI., 1995). These decreases in DA markers in the 
aged rodent brain are associated with a conspicuous decrease in spontaneous locomotion 
(Watanabe et aI., 1991; Hebert and Gerhardt, 1997). Direct evidence for a close 
connection between the DA system and motor behavior during aging is provided by 
several studies in animal models. These studies demonstrated that administration of the 
dopaminotrophic factor glial cell line-derived neurotrophic factor (GDNF) to aged non-
human primates (Maswood et aI., 2002) or rodents (Hebert and Gerhardt, 1997; Emerich 
et aI., 1996; Bowenkamp et aI., 1996) elevated DA markers in the striatum and the SN, as 
well as alleviated age-related motor deterioration. Further, rodents appear to provide an 
excellent model to study aging in this system, since alterations in different markers 
during aging appear to be consistent with those seen in the human brain (see above). 
A brief review of Parkinson's disease 
PD is a common neurodegenerati ve disease first described in 1817 (Parkinson, 
1817). PD is a progressive neurodegenerative movement disorder that is estimated to 
affect approximately 1 % of the population older than 65 years of age (Lang and Lozano, 
1998a, b). Clinically, most pati~nts present with the cardinal symptoms: bradykinesia, 
resting tremor, rigidity, and postural instability. A number of patients also suffer from 
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autonomic, cognitive, and psychiatric disturbances. The major symptoms of PO result 
from the profound and selective loss of DAergic neurons in the SN pars compacta (SNpc) 
(Braak et at, 2003). The pathological hallmarks of PO are round eosinophilic 
intracytoplasmic proteinaceous inclusions termed Lewy bodies (LBs) composed of alpha-
synuclein, neurofilaments, and ubiquitin (Goldman et aI., 1983) and dystrophic neurites 
(Lewy neurites) present in surviving neurons (Forno, 1996). ~owever, despite these early 
descriptions, the etiology of PO remains unclear. Possible mechanisms of cell death 
associated with PD include mitochondrial dysfunction caused by the inhibition of 
complex I leading to energy failure (Zeevalk et aI., 1998), oxidative stress caused by an 
increase in DA turnover resulting in generation of reactive oxygen species (ROS) 
(Olanow and Tatton, 1999), and glutamate excitotoxicity caused by massive activation of 
glutamate receptors on DAergic nigrostriatal neurons reSUlting in excess cytoplasmic 
Ca2+ (Mody and MacDonald, 1995, Olanow and Tatton, 1999). Recently, specific genetic 
defects-including a-synuclein, synphilin-l, ubiquitin carboxyl-terminal hydrolase Ll 
(UCH-Ll), and Parkin-have been identified as probable causes of PD. Additionally, 
exposure to pesticides, such as maneb, paraquat, and rotenone, has been positively 
correlated with an increased incidence of PD (Menegon et aI., 1998; Kotake and Ohta, 
2003). 
At least three types of DAergic neurons exist in the parkinsonian SN according to 
Hirsch et al. (2003). The first group is unaffected by the pathological process and are 
considered "healthy" surviving neurons. The second group is already undergoing the 
degenerative process and displays features of apoptosis or autophagic degeneration. The 
last group includes "suffering" DAergic neurons. These neurons may contain Lewy 
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bodies and neuromelanin in the absence of tyrosine-hydroxylase immunoreactivity. 
Within the Parkinson's SN, these "wounded" neurons make up roughly 20% of the 
surviving melanized neurons. This indicates that there may be many suffering neurons in 
the brains of PD patients that have ceased to function long before their actual cell death 
(Hirsch et aI., 2003), leaving a window of opportunity for neuroprotective therapy. 
There is also a topographical pattern of degeneration associated with PD. The 
loss of nigra} neurons follows a specific pattern with the more susceptible area located 
laterally in the ventral part of the SNpc (Hutchinson and Raff, 2000). This results in 
severe dopamine depletion in the striatum, responsible for the motor symptoms 
associated with PD, especially bradykinesia (slowness of movement), tremor, rigidity and 
loss of postural control (Goldman et aI., 1983). Although the pathological changes and 
motor dysfunction that characterize the disease are well documented, the mechanism(s) 
responsible for the death of dopaminergic neurons has yet to be clearly established, as 
discussed below. Therefore, most of the current treatment for the disease is largely 
symptomatic rather than neuroprotective. The most commonly prescribed drug for PD is 
levodopa (L-DOPA). L-DOPA is the natural precursor for dopamine (Cotzias et aI., 
1968). In 1957, Arvid Carlsson and colleagues demonstrated that giving animals the drug 
reserpine caused a decrease in dopamine levels and a loss of movement control. These 
effects were similar to the symptoms of PD. By administering L-DOPA to these animals, 
the symptoms were alleviated (Carlsson et aI., 1957). These findings led other researchers 
to try L-DOPA in human Parkinson's patients and found that it alleviated some of the 
symptoms in the early stages of PD. L-DOPA is converted to DA in the brain and 
partially replaces lost midbrain dopamine as, unlike DA itself, when it is charged, it can 
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cross the blood-brain barrier. While intake of L-DOPA reduces the severity of 
Parkinsonian symptoms suggesting that it is effectively transformed into dopamine within 
the SNpc, it also causes severe side effects such as nausea, vomiting, and altered blood 
pressure. Further, during the time-course of the disease, L-DOPA may cause 
hallucinations and dyskinesia (Chase et at, 1993; Fahn, 1996). Unfortunately, L-DOPA 
and other Parkinsonian drugs are only able to control the symptoms of the disease but not 
prevent on-going cell death and eventually it becomes ineffective once sufficient 
dopaminergic neurons are lost 
Possible mechanisms of Parkinson's disease 
Oxidative stress 
Dopaminergic neurons are believed to be particularly prone to oxidative stress 
due to their high rate of oxygen metabolism, low levels of antioxidants, and high iron 
content (see ego Luo and Roth, 2000). Dopamine is thought to be capable of generating 
toxic reactive oxygen species (ROS) via both its enzymatic and non-enzymatic 
catabolism (Halliwell, 1992). Specifically, dopamine oxidation can occur either 
spontaneously in the presence of transition metal ions or via an enzyme-catalyzed 
reaction involving monoamine oxidase (MAO). Oxidation of dopamine via MAO 
generates a spectrum of toxic species including H202, oxygen radicals, semiquinones, and 
quinones (Graham, 1978; Graham et aI., 1978). H20 2, produced during the metabolism of 
dopamine (Graham et aI., 1978; Maker et aI., 1981), can be converted into hydroxyl 
radicals (OR-). Hydroxyl radicals are highly reactive species capable of reacting with 
virtually every cellular macromolecule. Iron-mediated catalysis of hydroxyl radicals 
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could be a key pathogenic mechanism contributing to oxidative stress in PD, given that 
the iron levels in the SN are not only higher than in other areas of the brain (Gerlach et 
aI., 1994), but are increased by approximately 35% in PD patients compared to age-
matched controls (Dexter et aI., 1989; Sofic et aI., 1988). Conditions that increase brain 
concentration and/or turnover of dopamine could potentially increase the formation of 
reactive metabolites especially under conditions in which the ratio of available dopamine 
to antioxidant capacity is high (Hastings and Zigmond, 1994). Thus, dopamine oxidation 
may lead to the selective vulnerability of dopaminergic neurons to cell death in PD. 
Inflammation in PD degeneration 
Inflammation is an active defense reaction of multi-cellular organisms against 
diverse insults, designed to remove or inactivate noxious agents and to inhibit and reverse 
their detrimental effects (for review see Gao et aI., 2003, Liu et aI., 2003). The smallest 
of glial cells, microglia, are responsible for producing an inflammatory reaction to insults 
(Streit et aI., 2004). Normally, microglia are in a resting state characterized by ramified 
morphology. However, under subtle changes in their micro-environment or as a 
consequence of pathological changes, they transform into their activated state by 
displaying an amoeboid morphology (Kreutzberg, 1996). Activated microglia release 
pro-inflammatory molecules such as reactive oxygen species (ROS), interleukin (IL)-l~, 
tumor necrosis factor a (TNFa), and nitric oxide (NO), the overproduction of which can 
cause toxicity (Kennedy et aI., 1997, Hald et aI., 2005). 
There is increasing evidence suggesting that inflammation contributes to the 
pathogenesis of neurodegenerative disorders, which was previously thought to be purely 
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neuronal (see ego Allan and Rothwell, 2001; Hartmann et al., 2003; Hirsch et aI., 2003). 
In neurodegenerative diseases, inflammation may be triggered by protein aggregates, 
accumulation of other abnormally modified cellular constituents, molecules released from 
or associated with injured neurons or synapses, and dysregulation of inflammatory 
control mechanisms (Wyss-Coray and Mucke, 2002). In a study by McGeer and 
collaborators (1988), it was reported that a large number of reactive human leucocyte 
antigen-DR (IaA-DR)-positive microglial cells were located in the SN of patients with 
PD (McGeer et aI., 1988), Recent evidence suggests that a subpopulation of activated 
glial cells may be detrimental in PD and particularly so for suffering or wounded neurons 
as described by Hirsch and colleagues (2003). In a study assessing postmortem 
neuropathology of three subjects with MPTP-induced parkinsonism, gliosis and 
clustering of microglial cells around nerve cells were detected despite survival times 
ranging from 3-16 years (Langston etaI., 1999), Similarly, activated microglia and 
dopaminergic cell loss were found in the SN of primate's years after treatment with 
MPTP (McGeer et aI., 2003) and in the rats treated with rotenone (Sherer et aI., 2003). In 
another PD animal model (6-hydroxydopamine, 6-0HDA), rats also showed increased 
levels of the principle cytokine, TNFu, in the SN and striatum (Mogi et aI., 1999), in 
addition to microglia activation (Cicchetti et aI., 2002). Previous studies demonstrated 
that :METH caused an increase in reactive gliosis (Sheng et aI., 1994; Hebert and 
o'Callaghan, 2000) and microglial activation (Lavoie et aI., 2004; Thomas et aI., 2004a; 
2004b), as well as induction of certain inflammatory genes, including TNFa, 
cyclooxygenase-2 (COX-2), and., thiobarbituric acid (TBA), in the striatum (Flora et aI., 
2002; Kita et aI., 2000). These data suggest that not only ongoing nerve cell loss is 
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occurring but that activated microglial cells may cause further in neuronal degeneration 
(Langston et aI., 1999). Direct evidence of cell loss triggered by microglial activation 
comes from studies assessing in vivo effects of the gram-negative bacterial cell wall 
component lipopolysaccharide (LPS). LPS has been injected into the SN of rats causing 
microglial activation and degeneration of the dopaminergic system (Castano et aI., 1998; 
Herrera et aI., 2000). In vitro studies using mixed neuron-glia cultures treated with LPS 
demonstrated rapid microglial activation followed by neuronal degeneration (Gao et aI., 
2002). These studies suggested that SN DA neurons might be particularly sensitive to 
inflammatory processes in the brain. This concept has played a major role in the 
formulation of the overall hypothesis of this dissertation (see below). 
Recent evidence from a number of laboratories has indicated that stress-activated 
p38 MAP kinase modulates apoptosis. Effects of p38 MAP kinase are complex due to 
the existence of at least four isoforms (Ono and Han, 2000). The activity of p38 MAP 
kinase is stimulated by factors that induce apoptosis including trophic factor withdrawal, 
excitotoxic stimuli, and Fas activation (Kawasaki et aI., 1997; Xia et aI., 1995; Kummer 
et aI., 1997; Juo et aI., 1997). Previous results have shown that inhibition of p38 MAP 
kinase improved survival of rat dopamine neurons in vitro and after transplantation into 
hemiparkinsonian rats (Zawada et aI., 2001). In addition to its role in apoptosis, the p38 
MAP kinase signaling pathway was found to be a common mediator of microglial 
activation (Bhat et aI., 1998; Pyo et aI., 1998, 1999; Tikka et aI., 2001), along with ERK 
1/2 and JNK pathways. This microglial activation can mediate degeneration of DAergic 
neurons in the SN by increased expression of iNOS, COX-2, and other pro-inflammatory 
cytokines, effects that were abolished by inhibition of the p38 MAP kinase pathway 
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(Choi et aI., 2003). Therefore, inhibiting the p38 MAP kinase pathway may prove to be 
neuroprotective in neurodegenerative diseases. This hypothesis is examined in chapter 
IV. 
Methamphetamine and DA terminal degeneration 
Methamphetamine (l\ffiTH) is a widely used psychostimulant, that was first 
synthesized in Japan in 1893 (Suwaki et aI., 1997). Various countries, including the 
USA, used METH for its energy-promoting and performance-enhancing properties 
during World War II. These properties include feelings of enhanced well-being, 
heightened libido, increased energy, and appetite suppression (Logan, 2002). After the 
war, large quantities of METH were put on the civilian market, thus in citing Japan's first 
METH epidemic (Matsumoto et al., 2002). During the past decade, METH production 
and abuse has grown dramatically in the USA. US admissions for treatment of 
rvtETHlamphetamine abuse and dependence, increased by more than 500% from 1992 to 
2002, from 10/100,000 to 52/100,000 people 12 years of age or older (Substance Abuse 
and Mental Health Services Administration, Office of Applied Studies, 2004). This 
increase could be due to several factors, including longer lasting stimulant effects and the 
ease and low cost of producing and buying METH compared to cocaine (Anglin et aI., 
2000). 
High dose administration of METH results in long-lasting depletion of DA and 
serotonin (5-HT) in the brains of rodents and non-human primates (see ego Seiden et aI., 
1976; Kogan et aI., 1976; Wagner et aI, 1980; Woolverton et al., 1989). In addition, 
marked decreases in the activity of tyrosine hydroxylase and tryptophan hydroxylase, the 
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concentration of DA and 5-HT metabolites, the number of DA and 5-HT transporters 
(DAT, SERT), and the number of vesicular monoamine (VMAT) transporters' are 
associated with repeated administration of :METH (see ego Woolverton et aI., 1989; Lew 
et aI., 1997; Frey et aI., 1997; Villemagne et aI., 1998). Morphological studies suggest 
that the above reductions in presynaptic DA and 5-HT markers are a result of the 
destruction of DA and 5-HT axons and axonal terminals (Ellison et aI., 1978; Molliver et 
aI., 1990; Axt and Molliver, 1991), with little or no damage to cell bodies (Ricuarte et aI., 
1982; Woolverton et aI., 1989). These findings have been further substantiated by silver 
staining that detected terminal degeneration in the striatum of rvrnTH-treated animals 
(Ricuarte et aI., 1982; O'Callaghan and Miller, 1994). In this dissertation, the effects of 
aging on :METH-induced toxicity during young adulthood were examined. 
Methamphetamine enters axon terminals by way of DAT or SERT and displaces 
both vesicular and intracellular DA/S-HT (Brown et aI., 2000; Hogan et aI., 2000). As 
intracellular levels of DA rise, DA is oxidized by MAO reSUlting in increased levels of 
reactive oxygen species (ROS) and H20 2 (Figure 1-3). DA that is not oxidized by MAO 
becomes auto-oxidized to form reactive quinones that will further increase the formation 
of ROS causing oxidative stress. Because :METH is a cationic lipophilic molecule, it can 
diffuse into the organelles, including the mitochondria, where it disrupts the 
electrochemical gradient. By entering the mitochondria, METH raises the pH of the 
inner membrane matrix and reduces the activity of the acid enzyme A TP-synthase. Since 
ADP is not converted to ATP, the capacity to maintain the mitochondrial membrane 
potential is reduced (Davidson et aI., 2001). In addition, the increased formation of DA 
quinones causes the permeability transition pore (PTP) of the mitochondria to open 
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resulting in an increase release of calcium into the cytoplasm causing activation of the 
caspase-3 cell death pathway (Murphy et aI., 1999). 
In addition to the accumulation of cytoplasmic DA, extracellular DA levels rise 
due to the efflux of DA caused by the reversal of DAT function (Jones et aI., 1999). The 
excess extracellular DA activates postsynaptic DA receptors, thereby activating a 
polysynaptic loop causing an increase in cortical glutamate release into the striatum 
(Sonsalla et at, 1989; Nash and Yamamoto, 1992; LaVoie and Hastings, 1999; Imam et 
at, 2001; Stephans and Yamamoto, 1994). The increase of glutamate into the striatum 
causes activation of ionotropic and metabotropic glutamate receptors on the striatal DA 
tenninals to increase calcium influx (Tarazi and Baldessarini, 1999; Lipton and 
Rosenberg, 1994). Calcium increases the production of nitric oxide (NO), which inhibits 
complex IV of the electron transport chain resulting in the release of cytochrome c and 
activation of caspase cascades (Davidson et aI., 2001; Cleeter et aI., 1994). Similarly the 
formation of peroxynitrite (ONOO-) from NO and superoxide (02-) inhibits complexes I 
and II of the electron transport chain (Boveris et al., 2000). 
Methamphetamine causes an increase in core body temperature, that has been 
linked to the DAergic deficits produced by the drug (Bowyer et aI., 1994). The 
hyperthermic response may also contribute to the increase of ROS since prevention of 
hyperthermia attenuated the fonnation of ROS in the striatum (see ego Fleckenstein et aI., 
1997; Bowyer et aI., 1992). From these results, it seems that ambient temperature plays 
an important role in the magnityde of the neurotoxic effects of METH. Even though 
links have been established between body temperature and neurotoxicity of ·METH, little 
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IS known about the mechanistic role temperature plays in the observed striatal 
neurodegeneration. In this study, METH increased body temperature to a similar extent 
in GDNF/- and wildtype (WT) mice. 
METH toxicity, much like MPTP and 6-0HDA, has been used as a PD model 
(Kita et aI., 2003; Sonsalla et aI., 1992). Like MPTP, depending on the species or mouse 
strain and dose regimen, :METH-induced monoaminergic deficits vary in their duration 
and recovery over time. In mice, decreases in DA and 5-HT content and uptake as well as 
TH and tryptophan hydroxylase immunoreactivity endure for at least 6 months (Deng, et 
aI., 1999; Sonsalla et aI., 1992) or longer in some brain regions (Sabol et aI., 2000). 
:METH abuse is on the rise in the USA among young people and evidence is 
accumulating that the effects of :METH abuse on DA and 5-HT are prolonged. Even after 
protracted abstinence, DAT showed only a 20% recovery in former :METH abusers, who 
also demonstrated slower motor speed and deficits in verbal learning (Volkow et aI., 
2001a; 2001b). In this study, the long-term effects of METH in young adult mice on 
various monoaminergic markers and motor function were assessed. 
Neuroprotective treatments 
GDNF supports dopaminergic survival and function 
Neurotrophic factors regulate many critical aspects of neuronal ontongenesis, 
such as the number of neurons in a given population, neurite branching and 
synaptogenesis. GDNF also ;tids in adult synaptic plasticity and maturation of 
electrophysiological properties (for review see Calamandrei and Alleva, 1995). GDNF is 
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a member of the transforming growth factor-p (TOF-P) superfamily, along with artemin, 
persephin, and neurturin (Sariola and Saarma, 2003). These neurotrophic factors have 
been found to lend support to certain neuronal populations in the central nervous system 
(eNS), including midbrain DA neurons and motoneurons (Sariola and Saarma, 2003). In 
1993, GDNF was first purified and characterized as a growth factor promoting the 
survival of embryonic dopaminergic neurons in tissue cultures (Lin et aI., 1993) and in 
the developing and adult brain (Bowenkamp et aI., 1995; Hudson et aI., 1995). Later, 
GDNF was found to be a potent trophic factor for spinal motoneurons (Hendersen et aI., 
1994; Oppenheim et aI., 1995; Zum et aI., 1994), central noradrenergic neurons (Arenas 
et aI., 1995), as well as motor neurons of the cranial nerves (Hottinger et aI., 2000; 
Houenou et aI., 1996; Li et aI., 1995; Oppenheim et aI., 1995). In addition to its roles in 
the eNS, GDNF is critical for parasympathetic and kidney development and 
spermatogonial differentiation (Pichel et aI, 1996). 
GDNF signaling occurs through the activation of the receptor tyrosine kinase 
(RTK) Ret (Trupp et aI., 1998; 1999). Additionally, GDNF binds to the GDNF family 
receptor a (OFRa) bound to the plasma membrane by a glycosylphosphatidylinositol 
(GPI) anchor (Saarma, 2000). To date, four different GFRa receptors have been 
identified (GFRal-4), and they determine the ligand binding and activation specificity of 
Ret (Saarma, 2000). Briefly, GDNF first forms a high-affinity complex with GFRal. 
This complex then brings the two molecules of Ret together, triggering 
transphosphorylation of specific tyrosine residues in their tyrosine kinase domains that 
initiates intracellular signaling (Airaksinen and Saarma, 2002) (Figure 1-4). The mRNA 
for the two receptor components of the GFRa-Ret complex is expressed in the SN 
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(Nostrat et al., 1997; 00 et aI., 2005; Glazner et aI., 1998) whereas the mRNA for the 
growth factor protein is expressed in the striatum and in the SN; however to a greater 
extent in the striatum, supporting the notion that GDNF is a target-derived retrogradely 
transported growth factor for DA neurons (00 et at, 2005; Tomac et aI., 1995; Nosrat et 
aI., 1996, Trupp et aI., 1997). Once transported to the SN, the GDNF-GFRa1-Ret 
complex activates intracellular signaling cascades, including the MAP kinase pathway 
and phosp~oinositide 3-kinase pathway, both of which aid in neurite outgrowth in the 
nervous system, as well as contributing to neuronal survival (Kaplan and Miller, 2000). 
In addition to kinase activation, Ret signaling activates the phospholipase Cy (PLC-y) 
pathway, which regulates the intracellular level of Ca2+ ions by increasing the level of 
inositol (1, 4, 5)-trisphosphate. Lastly, GDNF signaling employs the Src-family kinases 
to elicit neurite outgrowth, neuronal survival and ureteric branching (Airaksinen and 
Saarma, 2002). 
GDNF promotes DA phenotype in vitro (Lin et aI., 1993), promotes the survival 
of injured DA neurons jn the nigrostriatal system and improves motor function in rodent 
and non-human primate models of PD (Bowenkamp et aI., 1995; Gash et aI., 1995; 
Gerhardt et aI., 1999; Granholm et aI., 1997; Kordower et aI., 1999). GDNF also been 
prevents lesion-induced deficiencies in DA neurotransmission in target areas (Cass et aI., 
1999). Previous studies have shown that GDNF protein levels are decreased in the SN of 
PD patients, suggesting that a loss of this growth factor may be related to DA function 
(Jenner and Olanow, 1998). Therefore, studies have been conducted by injecting GDNF 
into the striatum of PD patients, thereby reducing PD symptoms (Gill et aI., 2003). This 
study shows for the first time that direct intra-putamenal GDNF infusion in Parkinson's 
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disease patients can be tolerated for one year and leads to significant increases in 
dopamine storage in the putamen. GDNF is also beneficial as a supplement to intracranial 
transplants of DA neurons in patients (Mendez et aI., 2000), thus suggesting GDNF 
promotes the survival of stored DA neurons. 
A GDNF knockout model was developed to explore the role of GDNF in fetal and 
postnatal development (see Pichel et aI., 1996; Sanchez et aI., 1996; Moore et aI., 1996). 
Since GDNF-1- mice die at birth due to renal agenesis, studies from our laboratory have 
used fetal grafts from GDNF-1- mice to demonstrate that postnatal survival of 
mesencephalic DA neurons is dependent on GDNF (Granholm et aI., 2000; Lara et aI., 
2003; Burke et aI., 1998; Akerud et aI., 1999). Grafted midbrain tissue from GDNF/-
donors did not contain TH-positive neurons unless supplemented with GNDF at the time 
of grafting. Currently, it is of interest to examine the role of endogenous GDNF by 
assessing long-term effects of a partial GDNF depletion on the nigrostriatal dopamine 
system, since such deprivation may represent a genetic predisposition for DA 
vulnerability in the adult or middle-aged brain. This will be examined in Chapter II. 
Minocycline as a neuroprotective agent 
Minocycline is a second-generation semi-synthetic antibiotic belonging to the 
tetracycline family and is known to have anti-inflammatory (Tikka et aI., 2001a, b) and 
anti-apoptotic actions (Zhu et aI., 2002; Wang et aI., 2004). The interest in minocycline 
has grown in recent years because it easily crosses the blood-brain barrier and exerts 
powerful protective effects in the CNS. Minocycline is composed of the basic four-ring 
tetracycline structure, but a dimethylamino functional group on the 7th carbon position 
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gives this particular derivative highly lipophilic properties (Klein et aI., 1995; Shapiro et 
aI., 1997). Therefore, oral, intravenous, or intraperitoneal administration of minocycline 
will result in eNS penetration. According to the FDA, long-term treatment with this drug 
up to 200 mg daily is generally safe and well tolerated as demonstrated in clinical trials 
and tolerability tests in patients with rheumatoid arthritis, acne vulgaris, and Huntington's 
disease (Bonelli et aI., 2003; Goulden et aI., 1996; Stone et aI., 2003; Tilley et aI., 1995). 
In rare instances, late-onset fever (Grim et aI., 2003), lupus (Lawson et aI., 2001; 
Schlienger et aI., 2000), autoimmune hepatitis (Teitelbaum et aI., 1998), and 
hypersensitivity syndrome (Settgast et aI., 2003) have been reported as adverse effects of 
minocycline treatment. However, the most common reversible side effects have been 
reported with treatment, including digestive and vestibular disorders (Goulden et aI., 
1996; Shapiro et aI., 1997), staining of permanent teeth (Good and Hussey, 2003) or 
benign intracranial hypertension (Donnet et aI., 1992). Because minocycline is 
considered safe at high doses over long periods of time, it stands to reason that this drug 
could be considered for long-term treatment of neurodegenerative diseases. 
Minocycline's neuroprotective efficacy was first observed in experimental models 
of acute neurological disease, including global and focal cerebral ischemia (Y rjanheikki 
et aI., 1998, 1999) and traumatic brain injury (Sanchez Mejia et aI., 2001). Presently, 
minocycline has also provided neuroprotection against excitotoxicity (Tikka and 
Koistinaho, 2001; Tikka et aI., 2001), ~-amyloid neurotoxicity (Ryu et aI., 2004) and 
spinal cord injury (Stirling et aI., 2004). It has also been protective in neurodegenerative 
~ 
disease models such as the super oxide dismutase 1 (SOD 1) model of amyotrophic 
lateral sclerosis (Kriz et aI., 2002; Van Den Bosch et aI., 2002), the R6/2 mouse model of 
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Huntington's disease (Chen et aI., 2000; Wang et aI., 2003), and Ts65dn mouse model of 
Down syndrome (Hunter et aI., 2004). In the initial studies using PD models, 
minocycline protected against nigral toxicity of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) and 6-0HDA (Blum et aI., 2004; Wu et aI., 2002; Du et aI., 
2001). Beneficial effects of the antibiotic were observed in rodents injected with 6-
OHDA into the striatum. These results included reduced nigral dopamine cell 
degeneration and microgliosis (He et at, 2001). Therefore, clinical have been initiated 
for the possible treatment of PD (Ravina et aI., 2003) and Huntington's disease (Bonelli 
et at, 2003). These neurodegenerative diseases have recently been associated with 
neuroinflammation, apoptosis, or both, and the neuroprotection seen with minocycline is 
considered to be associated with its ability to inhibit apoptosis and/or microglial 
activation, therefore reducing the amount of cytotoxic factors released from microglia. 
Although the precise mechanism of minocycline's neuroprotection is unknown, 
the effects seem to be associated with the inhibition of caspase-1, caspase-3, inducible 
nitric oxide synthetase (iNOS) transcriptional upregulation, as well as with the inhibition 
of microglial activation, p38 MAPK cascade, and the release of cytochrome c from the 
mitochondria (see ego Zhu et at, 2002; Ou et aI., 2001; Chen et aI., 2000; He et aI., 2001; 
Wang et aI., 2003; Tikka et aI., 2001). Because of these findings, minocycline protects 
neuronal populations both indirectly (blocking inflammatory responses) and directly 
(reducing pro-apoptotic cell death pathways). The potential of minocycline as a 
treatment for METH-induced neurotoxicity that is associated with inflammation is the 
focus of chapter IV. 
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Purpose of the study 
This study examined the behavioral, molecular, neurochemical, and 
morphological ramifications of the central "dual-hit" hypothesis: A combination of 
drug exposure and genetic factors when an individual is young can increase 
age-related vulnerability of midbrain dopamine neurons during aging. 
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Figure Legends 
Figure 1-1. The major dopaminergic projections in the mouse brain. Dopamine neurons 
in the substantia nigra (A9) project to the dorsal striatum, whereas dopamine neurons in 
the ventral tegmental area (AlO) project to the nucleus accumbens, olfactory tubercle, 
ventral caudate-putamen (ventral striatum), ventral pallidum, amygdala, prefrontal cortex, 
cingulated cortex, and entorhinal cortex. Hypothalamic pathways are not shown for 
simplicity. 
Figure 1-2. Dopamine signal transduction pathways. Dopamine (represented by the 
small black diamonds) originates from tyrosine, which is converted to L-DOPA by the 
rate-limiting enzyme, tyrosine hydroxylase (TH). L-DOPA is then converted to dopamine 
by DOPA decarboxylase (DC). The transmitter is released into the synaptic cleft and acts 
on either Dl or D2 receptors. Binding of dopamine to Dl receptors results in the 
stimulation of adenylyl cyclase via Os protein to increase cyclic adenosine 
monophosphate (cAMP) formation and the activity of cAMP-dependent protein kinase A, 
leading to the phosphorylation of DARPP-32, thereby inhibiting protein phosphatase 1, 
increasing the phosphorylation state of phosphoproteins involved in physiological 
processes. Binding of dopamine to postsynaptic D2 receptors, a Oi coupled protein 
receptor, results in the inhibition of adenylyl cyclase, a decrease in cAMP and PKA, and 
a decrease in DARPP-32. Dopamine can also bind to presynaptic D2 receptors, 
autoreceptors, and inhibit the synthesis or release of dopamine. In the synapse, dopamine 
can be metabolized by catechoJ-O-methyltransferase (COMT) to 3-methyoxytyramine 
and then by monoamine oxidase-B (MAO-B) to homovanillic acid (RV A). Dopamine 
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can also be taken back up into the presynaptic terminal via the dopamine transporter 
(DAT) and metabolized to dihydrophenylacetic acid (DOPAC) via MAO-A. 
Figure 1-3. Possible mechanisms of methamphetamine neurotoxicity. High doses of 
:METH increase intracellular DA by inhibiting VMAT -2. This leads to rapid metabolism 
of DA by MAO-A, resulting in increased production of ROS and H202. DA is also auto-
oxidizes to form reactive quinones that attack cytoplasmic proteins and lipids and 
increases the production of ROS. Extracellular concentrations of DA also increase due to 
an efflux of DA through the DAT. This increase of extracellular DA results in receptor 
activation, thus activating polysynaptic loop, and increasing cortical glutamate release in 
the striatum and activation of NMDA receptors, thereby increasing calcium influx and 
inhibiting mitochondrial function. ROS and RNS production is then increased. METH-
induced hyperthermia is possibly another source of increased ROS fonnation. All this 
together leads to depletion of ATP and terminal degeneration. 
Figure 1-4. GDNF signaling cascade. GDNF (squares) are dimeric proteins and bind to 
GFRa-l co-receptors at high affinity_ The GFRa-l is anchored to the plasma membrane 
by a glycosyl-phosphatidylinositol (GPI) tail. After GDNF binds to GFRa-1, the 
complex is presented to the receptor tyrosine kinase Ret in the lipid raft, triggering Ret 
dimerization and transphosphorylation of their tyrosine kinase domains, resulting in 
downstream signaling of the ERKIMAP kinase and phophoinositide 3-kinase (PI3K) 
pathways for neurite outgrowth and neuronal survival, and the phospholipase Cy (PLCy) 
pathway which enhances neurottansmission and regulates intracellular levels of calcium 
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A Partial GDNF Depletion Exacerbates Age-Related Motor 
Dysfunction and Degeneration of Nigral Dopamine Neurons 
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INTRODUCTION 
Recent information indicates that the incidence of extrapyramidal symptoms 
increases significantly with age, to involve up to 50% of the population over 85 years of 
age (Bennett et aI, 1996; Kluger et aI., 1997). Epidemiological data suggest that this age-
related motor impairment results from a multifactorial process. Many studies suggest that 
the dopaminergic (DA) nigrostriatal system, although not the only system, is directly 
involved in age-related motor dysfunction (see ego Volkow et aI., 1998; Naoi et aI., 1999; 
Palmer and DeKosky, 1993; see also Ingram, 2000). In a human brain, the number of 
midbrain dopaminergic neurons is reduced 4.7-6.0% per decade after the age of 50 
(Peamley and Lees, 1991; Gibb and Lees, 1991). In addition, imaging studies have 
shown a substantial age-related decline in brain DA D2 receptors (Volkow et aI., 1996), 
DA Dl receptors (Suhara et aI., 1991), and DA transporters (Volkow et aI., 1996; see also 
Kaasinen and Rinne 2002, for review). Specific age-related deterioration in motor 
function has also been related to the DA transmitter system in animal models (see ego 
Hebert et aI., 1999; Cass et aI., 2002; Yurek et aI., 2000). Studies have shown alterations 
in DA uptake in the aged Rhesus monkey (Dejesus et aI., 2001), reduced DA release in 
aged F344 rats (Hebert and Gerhardt, 1997), as well as a reduction in DA receptor 
binding in aged mice (see ego Ingram 2000 for review). Additional studies indicate that 
aged rodents have an increased vulnerability to DA-specific neurotoxins such as 6-
hydroxydopamine in rats (6-0HDA; see Cass et aI., 2002) and I-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) in mice (Mandavilli et aI., 2000). Even though the 
mechanisms for age-related nigral neuron vulnerability are unknown, it has been 
suggested that a reduction in support systems such as growth factors increases the 
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susceptibility of the substantia nigra (SN) DA neurons to external stressors and toxins 
(see ego Yurek and Fletcher-Turner, 2000; 2001). 
GDNF is a member of the transforming growth factor-p superfamily of 
neurotrophic factors (Krieglstein et aI., 1995; Saarma, 2000). Systems which are 
dependent on GDNF for their survival include kidneys, spinal cord motor neurons, 
sensory neurons, and cranial nerve motor neurons (for review, see Bates, 2000; Saarrna et 
aI., 2000; Malcangio, 2003; Sah et aI., 2005). GDNF is also required for the survival, 
high-affinity DA uptake, and neurite outgrowth of cultured midbrain DAergic neurons 
(Lin et aI., 1993) and promotes recovery of behavior and morphology in rodent and 
nonhuman primate models of Parkinson's disease (PD; Bowenkamp et aI., 1995; Gash et 
aI., 1995; Lindner et aI., 1995; Mandel et aI., 1997; Kordower et aI., 1999; Cass et aI., 
1999; Granholm et aI., 2000). Importantly, GDNF is decreased in the SN of PD patients 
(Jenner and Olanow, 1998) and also in normal aged rodents (Yurek et aI., 2000) 
suggesting its involvement in motor dysfunction and DA neuron degeneration and has 
recently been used as an experimental therapeutic agent for patients with PD (Gill et aI., 
2003). 
A GDNF knockout model was developed to explore the role of GDNF in fetal and 
postnatal development (see Pichel et aI., 1996; Sanchez et aI., 1996; Moore et aI., 1996). 
Early development of mesencephalic DA neurons was unaffected in GDNF-1- mice 
possibly because the major apoptotic waves for midbrain DA neurons occur on postnatal 
days 2 and 14 in the mouse (00 find Burke, 1997; Mahalik et aI., 1994). Since GDNF -1-
mice die at birth due to renal agenesis, studies from our laboratory have used fetal grafts 
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from GDNF-1- mice to demonstrate that postnatal survival of mesencephalic DA neurons 
is dependent on GDNF (Granholm et aI., 2000). In order to examine the role of 
endogenous GDNF in a mouse model, we have examined long-term effects of a partial 
GDNF depletion (GDNF +/) on the nigrostriatal DA system throughout the life-span. Due 
to the fact that GDNF is also involved in renal development, we performed routine 
assessments of kidney size, morphology, and function throughout this longitudinal study 
of male GDWI- mice. 
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MA TERIALS AND METHODS 
ANIMALS: Male GDNF heterozygous (GDNF +1-) mice were compared to their wildtype 
(WT) littermates in all experiments. The nonfunctional allele for the GDNF gene was 
generated by replacing part of the third exon that encodes GDNF protein with a cassette 
expressing the selectable marker neomycin phophotransferase, as described previously in 
detail (Pichel et aI., 1996; Granholm et aI., 1997a, b; 2000). Heterozygous offspring are 
viable and fertile, whereas mice homozygous to the mutant GDNF allele (GDNF -1-) die 
within 24 hours of birth. The mice for this study were bred locally at the Medical 
University of South Carolina, on a C57BU6J background according to NIH approved 
protocols. The mice were housed in groups of 3-4 to a cage and had free access to food 
and water. They were maintained under 12-h light: 12-h dark cycle and at an ambient 
temperature of 20-22°C and were given water and mouse chow ad libitum. 
peR GENOTYPING: Genomic DNA was prepared from a 1 cm sample of tissue from 
the tail. The tissue was homogenized in 0.2 M NaCI, 5 mM EDTA, 100 mM Tris, pH 8.5, 
0.2% SDS and 400 J.lglml proteinase K overnight at 55°C with agitation. After 
centrifugation (12,000 rpm), DNA was precipitated from the supernatant with one 
volume isopropanol, pelleted, washed twice with 70% ethanol, and re-suspended in 500 
JlI sterile water. The DNA was assayed for the presence of the WT or knockout allele in a 
single peR reaction using WT primer mix and knockout primer mix. PCR was 
performed in a 50 J.lI reaction volume containing 2 J.lI of genomic DNA, 2 J.lM of each 
primer,5 mM MgCI2, 200 J.lM each of dATP, dGTP, dCTP, and dTTP, and one unit Taq 
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polymerase. The genomic DNA was amplified for a total of 35 cycles and the products 
analyzed for the presence of the WT or -/- allele on a 1.3% agarose gel. Amplification of 
the WT allele gave a band of 344 bp, while the mutant allele gave a band of 255 bp 
(Pichel et aI., 1996). 
UREA AND CREATININE ASSAYS: Since GDNF-1- die at birth due to kidney agenesis, 
we wanted to examine if kidney dysfunction would occur also in GDNF'- mice with age, 
and if such alterations may interfere with alterations in brain parameters or behavior. 
Therefore, Quantichrome Urea Assay (DIUR-OIK) and Quantichrome Creatinine Assay 
(DIeT-500) were utilized to determine the levels of urea and creatinine, respectively, in 
serum of all groups at 8, 12, and 22 months of age. These services were performed by 
DLAR. Urea measurements reflect the glomerular filtration rate, which is often used as a 
criterium for kidney function. The urea assay measures urea in blood or urine without any 
pretreatment in 5 minutes. This assay uses a chromogenic reagent that forms a colored 
complex specifically with urea and the intensity of the color (measured at 520 nm) is 
directly proportional to the concentration of urea in the sample. As little as 5 microliter of 
sample is needed to perform the assay and the linear detection range is 0.006 mgldl to 
100 mgldl (17 mM). The creatinine assay is also a direct and simple procedure that 
assesses kidney function by measuring creatinine directly in the biological sample (blood 
or urine). This procedure also involves a chromagenic reagent that forms a colored 
complex specifically with creatinine and the intensity of the color (measured at 510 nm) 
is directly proportional to the concentration of creatinine in the sample. The same amount 
(5 microliter) is needed for this assay and the detection range is 0.10 mgldl to 100 mgldl 
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(8-8.8 mM). Trunk blood was obtained from both genotypes at the time of sacrifice at 8, 
12, and 22 months of age (n=10 per group). In addition, kidneys were dissected and 
measured along the longitudinal axis (Figure lA), and were fixed with 10% 
formaldehyde for sectioning and pathological evaluation. 
ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA): GDNF levels were assessed 
using a commercially available assay kit from Promega according to our standard 
protocol (Albeck et aI., 2003). In brief, flat-bottom plates were coated with the 
corresponding capture antibody, which binds the soluble captured neurotrophin. The 
captured neurotrophin was bound by a second specific antibody, which was detected 
using a species-specific antibody conjugated to horseradish peroxidase as a tertiary 
reactant. All unbound conjugates were removed by subsequent wash steps according to 
the Promega protocol. After an incubation period with chromagenic substrate, color 
change was measured in an ELISA plate reader at 450 nm. Using these kits, GDNF can 
be quantified in the range of 7.8-500 pglml. For each assay kit, cross-reactivity with other 
trophic proteins is <2-3%. GDNF was expressed as pglmg tissue. These assays were 
perfonned by Alfred Moore in Dr. Granholm's lab. 
LOCOMOTOR TESTING: GDNF +/- and WT mice were tested at various ages (4, 8, 12, 
16, and 20 months of age) to evaluate the effects of a partial GDNF deletion on motor 
activity throughout the animal's lifespan. Locomotor activity (total distance traveled) 
was assessed in a Digiscan Antmal Activity Monitor system for one hour (Omnitech 
Electronics Model RXYZCM(8) TAO, Columbus, OH). The details of the apparatus 
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have been described previously (Halberda et aI., 1997). On the day of testing, the mice 
were transferred from the animal colony into the laboratory in groups of six and tested in 
a darkened environment. Data were collected in 5-min intervals for one hour at the same 
time of day (Sam to 12 am) for each test period. 
ACCELERATED ROTAROD: Motor coordination was evaluated using an accelerating 
rotarod treadmill (Ugo Basile, Verese, Italy). The mice were trained to remain on the 
rotarod for 10 min at a set speed of 4 rpm over a period of 2 days prior to actual testing. 
Mice were then tested for their ability to remain on the rotarod at increasing rotation 
speeds of 4, 8, 16, 24, 32, and 40 rpm. During these tests, the animal was allowed a 
maximum of 5 min at each rotation speed and 5 min rest between each test. Mice were 
tested for 3 consecutive days, and the results averaged to obtain a single value for each 
animal at a given rotational speed on a given day (as adapted from Rozas et aI., 1997). 
IMMUNOHISTOCHEMISTRY: For histochemical analysis, mice were anesthetized with 
halothane and perfused transcardially with saline followed by 4% paraformaldehyde in 
phosphate buffer (O.IM, pH 7.4). The brains were removed, postfixed in 
paraformaldehyde for 48 hours, and then transferred to 30% sucrose in O.IM phosphate 
buffered saline (PBS) for at least 24 hours before sectioning. The midbrain was sectioned 
on a cryostat (Microm, Zeiss, Thornwood, NY, USA) at 45 f.lm. Every 3rd section 
throughout the nigra region was processed for free-floating immunohistochemistry using 
a polyclonal antibody against tyrosine hydroxylase (TH, Pel-Freeze Inc., Roger, AZ, 
USA). Immunohistochemistry was performed according to our standard protocol 
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(Granholm et aI., 1997, Zaman et aI., 2003). Briefly, free-floating serial sections were 
treated with H202, methanol, and O.OIM Tris buffer saline (TBS, pH 7.6; 1:2:7 
respectively) for 15 minutes to quench endogenous peroxidase activity. Sections were 
permeabilized in TBST (tris buffer with 0.9% sodium chloride and 0.25% TritonX-100) 
and treated for 20 minutes with sodium m-peroxidate (O.IM) in TBS. To block non-
specific binding sites, sections were incubated in 10% normal goat serum (NGS, Sigma) 
in TBST for 30 minutes at room temperature. Sections were incubated with the primary 
antibody (1:1000) in TBST with 3% NGS at room temperature for 24 hrs. Following 
washing in TBST, sections were incubated with an appropriate secondary antibody 
(1:200, Vector Labs, Burlingame, CA) and incubated subsequently in the avidin-biotin 
complex (ABC kit, Vector Labs). 3'3' Diaminobenzidine (DAB, Sigma) was used as a 
chromagen to develop the reaction using 0.05% of 3% H202. Nickel ammonium sulfate 
(2.5%, Sigma) was used to enhance the reaction. Sections were mounted on glass slides 
and covers lipped with DPX. 
STEREOLOGICAL CELL COUNTS: Quantitative estimates of the total number of TH-ir 
neurons in the substantia nigra (SN) were achieved using an unbiased, stereological cell 
counting method (see Gundersen et aI., 1987; Granholm et aI., 2002; Hunter et aI., 2004 
a-c). Briefly, the optical fractionator system consists of a computer assisted image 
analysis system including a Nikon Eclipse E-600 microscope hard-coupled to a Prior 
H128 computer controlled x-y-z motorized stage, an Olympus-750 video camera system, 
a Micron Pentium III 450 computer, and stereological software (Stereoinvestigator@, 
MicroBrightField Inc.; Colchester, VT). The SN was outlined under low magnification 
(lOX) on every 3rd section through the rostro-caudal extent of the midbrain, and the 
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outlined region was measured with a systematic random design of disector counting 
frames (100 x 100 urn). Actual mounted section thickness was found to be 35-37 J.lm, 
and a 2 Jlm guard zone was set for the top and bottom of each section. A 40X objective 
lens with a 1.4 numerical aperture was used to count cells within the counting frames. 
STATISTICAL METHODS: The effects of age and genotype on motor activity were 
assessed with linear regression models that included age, genotype, and their interaction 
as covariates, and horizontal activity as the dependent variable. One regression model 
treated activity scores at ages 4, 8, 12, 16, and 20 months as repeated measures. Since a 
primary interest was the impact of GDNF reduction on changes in motor activity across 
ages, a second regression model was completed adjusting for genotype-related 
differences at 4 mos as a confounding covariate. Rotarod data were analyzed using a 
random-effects regression model that included age, genotype, rotarod speed, test day, and 
all possible 2-way and 3-way interactions as fixed covariates, and intercept as random 
effect in order to account for correlation among repeated measures. A step-wise 
regression procedure was used in the random-effects model fitting to identify most 
influential covariates. Significant 3-way interactions were resolved by first fixing one 
covariate involved in the 3-way interaction at anyone of its levels, and re-fitting the 
model that included only the 2-way interaction of the other two covariates. This model 




Kidney junction, weight gain and survival rates of GDNpl- mice: Since GDNF is known 
to affect kidney function and homozygous GDNP-I- mice suffer from kidney agenesis (see 
ego Pichel et aI., 1996), kidney morphology and function were examined at different ages 
in GDWI- mice and controls. Kidney size (Figure 2-1A) and weight (not shown) were 
not significantly different between any of the groups. Parameters indicative of kidney 
function (creatinine (CRT) and blood urea nitrogen (BUN)) were compared between the 
two genotypes at different ages (Figure 2-1B and C), and were also found to be nonnal, 
and within the normal range of C57 mice, in Figure 2-1B. In terms of general weight gain 
and survival rates of GDWI- compared to WT mice, we found that the two genotypes 
did not differ from each other in body weight throughout the study (at 3 weeks: WT 
10.9+/-0.7 g; GDWI-: 10.8+/-0.7 gram). Further, the mortality rate was similar between 
the two groups and attrition reached a mean of 16% in both groups by the age of 24 
months. Thus, there was no increased attrition rate or altered body weight with the partial 
deletion of the GDNF gene. 
GDNF protein levels. In order to determine whether GDNp/- mice did indeed have 
lower GDNF levels throughout life, we examined GDNF protein levels using ELISA in 
the striatum of 4, 12 , and 18-21 month old male mice of both genotypes (Figure 2-1D). 
At 4 and 12 months of age, GDWI- mice exhibited a significant reduction (34-35%) in 
striatal GDNF protein levels compared to age-matched WT controls. In addition, striatal 
GDNF levels in mice ranging in age from 18 to 21 months of age were significantly 
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reduced in GDNP+I- mice by displaying a 42% reduction compared to WT mice. No 
significant age-related decreases were seen in either genotype with age. This finding was 
previously confirmed this throughout the life-span in female GDNF/- mice (Griffin et 
aI., 2006). 
Effects of a partial GDNF deletion on spontaneous motor activity. Spontaneous motor 
activity for male GDNpl- and WT mice at four-month intervals from 4 to 20 months of 
age is summarized in Figure 2-2, showing longitudinal measures of 10 GDNF/- and 8 
WT mice. At 4 and 8 months of age, spontaneous locomotion of GDNF/- mice was 
comparable to that of age-matched WT mice (Figure 2). Between 8 and 12 months of 
age, GDNF/- mice exhibited a 50% decline in activity and were 54% below activity of 
age-matched WT mice. WT mice did not exhibit a significant decline in motor activity 
until 16 months of age, where they displayed a 36% decline in activity. Two linear 
regression models were fitted that included age, genotype, and age by genotype 
interaction as covariates and motor activity as dependent outcome. The first model 
treated motor activity measures generated by each animal across time as a repeated 
measure. The second model treated total motor activity measures at age 4 months as a 
covariate and was adjusted in the model to explore the rate of decline as a factor of aging 
and genotype. Neither model yielded a significant age by genotype interaction (p>O.65 in 
both models); however, motor activity was significantly lower for GDNF/- than for WT 
mice for each model (p<O.OI7 in both models). The absence of a significant interaction 
was due to the large variation all)ong different subjects within groups. Regardless of age, 
WT mice had significantly higher mean activity (393.0+10.6 em traveled over a 15-min 
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interval) compared to GDW'~ mice (276.7+9.2 cm traveled over a IS-min interval). A 
two-sided t-test to compare these two means yielded a p-value <0.001. 
Accelerating rotarod performance in GDNP+/~ mice. To assess the impact of a partial 
GDNF deletion on motor coordination and learning, young (8 month old) and aged (20 
month old) male GDW'- and WT mice were compared on their ability to remain on the 
accelerating rotarod device (see Methods). Figure 2-3 suggests a potential three-way 
interaction between age, genotype, and rotarod speed. These data were fitted with a 
random effects model that included age, genotype, rotarod speed, test day, and all their 
two-way and three way interactions as fixed covariates and intercept as random effect. 
The three-way interaction among age, genotype, and rotarod speed was highly significant 
(p<O.OOOl). To further explore the impact of age, speed, and genotype on the rotarod 
time, we fitted separated random-effects models to different subsets of animals (i.e., to 
fix the level of age). The subsets were the young (8 months) and aged (20 months) mice. 
A Step-wise procedure was used in model selection. In the final models, the genotype 
effect was not significant (p=0.60) for the young group. In contrast, for the aged animal 
group, genotype was significant through its interaction with the rotarod speed (p=O.004). 
The time mice remained on the rotarod as the speed increased declined more rapidly for 
GDNF'- compared to WT mice. Additional analysis indicated that with continued 
practice (Day 3, Figure 2-3), the GDWI- mice overcame this deficiency to some extent 
(Le., on the third test day GDWI- mice remained on the rotarod for a longer period of 
time as speed increased than was observed on earlier test days (p<O.OOl for both age 
groups). Both GDNF/- mice and WT mice increased their performance at a similar rate 
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since the genotype did not interact with the test days (p=0.2180). However, when we 
examined rotarod time on the last test day, significant speed by genotype interaction was 
still present in aged animals (p=0.043) but not in young animals. Again, no genotype 
effect was found in young animals (p=0.37). 
Effects of GDNF loss on TH immunohistochemistry. The SN from male GDNP'- and 
WT mice were processed for TH immunohistochemistry at ages 4, 8, 12 and 20 months 
in order to quantify the morphological effects of a partial GDNF loss. Since the motor 
activity study in Figure 2-2 was longitudinal, morphological studies included different 
sets of mice for each age (10 WT, 10 GDNF'-) except for the oldest group. Sample 
morphology from each group is shown in low magnification (Figure 2-4), in high 
magnification (Figure 2-5 medial SN), and cell counts of total number of neurons per 
animal are summarized in Figure 2-6. 
Stereological cell counts of TH-ir neurons. There was no significant difference in the 
total number of TH positive neurons in the SN between genotypes in the 4 month old 
mice (Figures 2-4 A, B) and 8 month old mice (Figures 2-4 C, D). However, the 12 
month old GDNF'- mice had a significant decrease in SN TH-positive neurons compared 
to the WT controls, resulting in a mean decline of 19% (Figures 2-4E, 2-4F, and 2-6, 
n=10, p<O.OI). The decrease in the number of TH-positive neurons between genotypes 
was also apparent at the 20-month-old time point with a 15% reduction (n=10, p<O.05). 
In addition, the 12-month-old apNF'- mice had a 19.7% reduction of total TH-positive 
neurons compared to 8-month-old GDNF'- mice (n=10, p<0.05), unlike the WT mice 
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DISCUSSION 
In the present study, we found that male GDNF+'· mice exhibited a progressive 
decline in spontaneous motor activity, motor coordination, and SN TH-ir neurons, over 
the course of 20 months that was greater than WT mice. In addition to the abnormalities 
noted in the present experiment, GDW'· mice have a loss of locus coeruleus 
noradrenergic (LC-NE) neurons (Zaman et aI., 2003), as well as a cognitive decline with 
age reported by others (Gerlai et aI., 2003). Similarly, Airavaara et aI., (2004) 
demonstrated increased dopaminergic postsynaptic activity in GDW'- mice at an early 
age, suggesting compensatory alterations in dopaminergic pathways. In contrast to these 
deficiencies, we did not find altered kidney function in GDW'- at any age, and weight 
gain and survival rate were similar between the two groups as well. 
GDNF is required for ureter bud formation and branching during metanephros 
development of the kidney, and is essential for proper innervation of the gastrointestinal 
tract (Piche! et ai, 1996). Thus, mice lacking both copies of GDNF lack kidneys and die 
at birth (Pichel et aI., 1996), whereas the loss of one allele for GDNF results in 
approximately 30% fewer but normal sized glomeruli in young mice at postnatal day 30 
(Cullen-McEwan et aI., 2001). In 14 month old GDWI- mice, the same authors found 
that the animals had 30% fewer glomeruli than WT mice but that the remaining glomeruli 
were larger. This increase in glomeruli size provided an adaptation such that kidney 
filtration rate was normal in these animals (Cullen-McEwan et aI., 2003). Data from the 
current experiment demonstrate that both kidney size and BUN/creatinine levels in serum 
from mice of all ages confirmed these findings by Cullen-MCEwan et al (2003), and 
further demonstrated that normal kidney function was sustained throughout this 
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experiment (up to 22 months of age). In addition to the kidney abnormalities observed in 
fetal GDNF knockout mice (Pichel et aI., 1996), the absence of GDNF prevents 
differentiation and ameloblasts and odontoblasts, and the enamel matrix and predentin 
layers are absent (de Vicente, J. C., Cabo, R. et aI., 2002). These peripheral defects, 
however do not appear to impair the feeding behavior of GDNF/- mice, and animals 
maintain similar weights as WT mice raised on the same diet. In addition, GDNF/-mice 
have no greater mortality at least up to 24 months of age, compared to WT littermates 
(personal observations). Thus, it is unlikely that abnormal kidney function or other 
peripheral dysfunctions account for the alterations in DA morphology and motor 
behavior observed in the present experiment. 
The age-related reduction of spontaneous locomotion observed in the WT mice in 
the present study is similar to what has been reported for this mouse strain (C57BI/6J) in 
previous publications (Dean et aI., 1981). GDNF+1- mice exhibited a greater rate of motor 
decline than WT mice in the present study. Their activity declined several months earlier 
than that of WT mice. The data suggest that GDNF is involved in the regulation of 
spontaneous motor function, either via one or several transmitter systems, and that this 
influence becomes more pronounced with age. 
It is possible that the "catch up" of the WT mice with the GDNF/- mice at later 
ages is associated with a decline in striatal GDNF with normal aging. This interpretation 
is consistent with reported GDNF decrease with age in the rat (Yurek et aI., 2001). Thus, 
lower GDNF in WT mice at the older ages may result in lower activity equivalent to 
GDNF/- mice. In fact, previous studies in both rats (Hebert and Gerhardt, 1997) and 
aged non-human primates (Gash et aI., 1996) suggest that this may, indeed, be the case 
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sInce GDNF injections in aged individuals of both specIes gave nse to increased 
locomotion and increased health of DA neurons and DA innervation of the striatum. 
Even though a slight decrease in GDNF was observed in the oldest group (18-21 
months), the data presented here do not indicate any significant loss of GDNF in aged 
WT mice that could prove this hypothesis. 
Animal models of PD with acute DA lesion paradigms, such as 6-0HDA and 
MPTP-Iesioned animals, also exhibit lower spontaneous locomotion, even though this 
deficit develops rapidly after the lesion (eass et aI., 2005; Tamas et aI., 2005; Deumens et 
aI., 2001). The present model may represent an interesting model for motor dysfunction 
in animals, as the deficit developed more slowly than that seen in the lesion models, and 
can thus be used for prevention or rescue studies that extend over several months, that 
mimicks the situation in humans more closely. 
The rotarod is widely used to assess motor coordination in experiments that 
evaluate motor injury, pharmacological treatments, or genetic manipulations (see e.g. 
Fenton et aI., 1994; Wagner and Walsh 1987; Hamm 2001; Smith and Stoops 2001). In 
the present study, rotarod performance was influenced by a three-way interaction of age, 
genotype, and rotarod speed. Motor coordination deteriorated with age and speed of 
rotation for both genotypes, although significantly more so in the GDNF/- than in the 
WT mice. Performance improved across days of testing suggesting that motor learning 
could occur in all groups, albeit to a lesser degree in GDNpl- mice. The highly 
significant reduction in performance is not surprising, since motor coordination is one of 
the first behavioral components J<nown to deteriorate with normal aging in rodents (see 
ego Bickford et aI., 1992). However, it is important to note that aged WT animals were 
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able to learn the task by day 3 to the same extent as the young WT animals, leaving a 
defect in the highest speed only in aged GDWI- mice. The neuronal substrate for this 
deficit could be related to noradrenergic as well as DAergic neurotransmission, since 
both of these systems have been implicated in this particular behavioral task (Bickford, 
1995; McEntee et aI., 1987; Mason and Iversen, 1977). Since this mouse model exhibits 
loss of both LC TH-ir neurons (Zaman et aI., 2003) and SN TH-ir neurons (present 
study), either, or both of these transmitter systems could mediate the motor deficit. 
Targeted delivery of GDNF to either LC or SN neurons in GDWI- mice would reveal if 
one or both of these systems are involved in the motor deficit of aged mice, and this will 
be the focus for future studies. 
DAergic pathways are especially susceptible to the effects of normal agIng 
(McGeer et aI., 1977; Severson et aI., 2002; Carlsson 1987; Seeman et a!., 1987; Kish et 
aI., 1992). In the present study, WT mice exhibited a small but significant decline (20%) 
of TH-ir neurons with age, as previously reported for this mouse strain (McNeill and 
Koek, 1990; Tatton et aI., 1991). GDWI- mice were distinguishable from WT mice with 
a greater overall decline (35.7%) of TH-ir neurons that occurred earlier in the life span, 
between 8 and 12 months of age rather than 12-20 months as seen in WT mice. Further 
morphological inspection revealed a far greater loss of fibers and terminals in this region 
in GDWI- mice compared to WT mice. This result suggests that GDNF may be 
involved in maintenance of this neuronal population, especially during aging. Puture 
studies will determine if neurons eventually die or actually just lose their phenotype. We 
have shown in preliminary studies that both a-synuclein and D2 receptor mRNA are 
upregulated in the striatum of middle-aged GDNP+I- mice (12 months of age, Boger et aI., 
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2004). An upregulation of D2 receptor mRNA has been associated with dopamine 
denervation of the striatum and is reflected by increased binding to the D2 receptor 
(Angulo et aI., 1991; Coirini et aI., 1990; Creese et aI., 1977; Xu et aI., 2005). In 
addition, although the function(s) of a-synuclein are still unknown, this protein has been 
postulated to be involved in the physiological maintenance of DAergic synaptic 
homeostasis and plasticity-a physiological function that may be altered in neurological 
disorders such as PD (Sidhu et aI., 2004; Lotharius and Brundin, 2002; Perez and 
Hastings, 2004). Specifically, it has been shown that mouse models which over-express 
a-synuclein may undergo histopathological alterations similar to those seen in PD as 
well, suggesting that this is a biomarker for DA degeneration and PD (Poon et aI., 2005). 
It is therefore interesting to note that the GDNF/- mice also over-express a-synuclein in 
addition to the other findings reported here. 
Collectively, the GDNF heterozygous mouse has fairly subtle alterations in basal 
motor function and DA morphology as aging progresses, and most alterations are evident 
also in the WT mice with aging. We propose that this genetic predisposition may set 
individuals up for increased vulnerability when presented with an environmental insult 
and that a combination of intrinsic and extrinsic factors when an individual is young can 
increase aging-related vulnerability of midbrain dopamine neurons. Thus, our research 
group has proposed a "dual-hit" hypothesis of neurodegeneration in which a combination 
of factors during early pre- or postnatal development enhances the vulnerability of DA 
neurons leading to altered neuronal functioning during aging (see ego Sarabi et aI., 2003). 
The animal model will provide .. an opportunity to determine if genetic predisposition 
coupled with a prenatal or postnatal neurotoxin may enhance aging-related 
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neurodegeneration resulting in motor disorders. We currently have data suggesting that 
toxicity of a binge methamphetamine exposure given during early life excacerbates 
neurodegeneration in GOWI- mice with aging (Boger et aI., 2005); the same is true for 
prenatal exposure to lipopolysaccharide (Zaman et aI., 2005). Thus, GDWI- mice 
represent a a model that can be utilized in combination with environmental toxins for 
examination of the dual hit hypothesis. 
In conclusion, the present study demonstrates that a life-long reduction of GONF 
leads to progressive, albeit modest, neurodegenerative alterations in the nigrostriatal 
system with aging. Evaluation of open-field locomotor testing and performance on the 
accelerating rotarod revealed that the GO Wl- mice had deficient motor function and 
coordination with age compared to WT mice. Stereological cell counts and 
measurements of TH-ir neurons indicated that with aging, the GDWI- mice had 
accelerated morphological alterations in the SN. These data provide evidence for a role 
for GDNF in the maintenance of the nigrostriatal DAergic system, and als<? provide a 
novel animal model for therapeutic intervention, both in terms of prevention and rescue, 
of aging DA neurons. 
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FIGURE LEGENDS 
Figure 2-1. Measurement of kidney sizes in 16 GDNF+/~ and 13 WT control mice at 
12 months of age. There was no genotypic difference. B = Creatinine levels in 8, 12, and 
22 month old GDNF'- and WT mice (total n = 58). There were no genotypic differences 
at any age. Normal range in the young adult mouse of the same breed is depicted over the 
graph as a gray transparent box. C = BUN levels in the same mice, showing that there 
was no alteration in BUN levels at any age tested. D = GDNF protein levels in bilateral 
striatum were significantly lowered throughout the lifespan in GDNF'- vs. WT mice 
(total n=43) (p<O.05). (*p<O.05) 
Figure 2-2. Horizontal activity was lower from 12 to 20 months of age in GDNF+1- vs. 
WT mice. No difference existed in spontaneous locomotion at 4 and 8 months of age 
between the genotypes. At 12 months of age, GDNF'- mice displayed less locomotion 
compared to the WT mice (p<O.OOl). Also, GDNF'- mice exhibited a decrease in motor 
activity between ages 8 and 12 months (p<O.OOl). This decrease in activity for GDNF 
+/- mice continued through the 20 month time-point, suggesting an age-related deficit 
(p<O.OOl). (*p<O.05, ***p<O.OOl) 
Figure 2-3. Accelerating rotarod performance was deficient in aged GDNF+1- mice. 
A three-way interaction existed among age, genotype, and rotarod speed (p<O.OOOl). No 
genotypic effect existed in the young animal group but a significant interaction of 
genotype and rotarod speed did .. exist in the aged animal group (p=O.004). After daily 
testing, the time spent on the rotarod at the various speeds became significantly more on 
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earlier test days (p<O.OOI for both age groups). Both GDNF/- and WT mice increased 
their performance at a similar rate (p=0.2180), suggesting no effect of genotype on 
learning. However, a significant speed by genotype interaction was still present on the 
last day of testing in the aged mice (p=0.043). 
Figure 2-4. TH-ir declines in neurons of 12-20 month old GDNF+1- mice. TH 
immunohistochemistry of midbrain sections from WT (A, C, E, G) and GDNF/- (B, D, 
F, H) mice. Note that at 4 months (A, B) and 8 months (C, D) of age, no morphological 
differences exist between the two genotypes. However, at 12 months of age (E, F), 
GDNF/- mice exhibit a decrease in TH-ir neurons in the SNpc as well as a decrease in 
fiber density of the SNpr compared to WT mice. The effect of a partial depletion of 
GDNF is also evident at 20 months of age (G, H). (Scale bar: 200 Ilm) 
Figure 2-5. TH immunostaining in medial substantia nigra. Photomicrographs of TH 
immunohistochemistry in the medial region of the SN. Fiber density and the number of 
TH-ir neurons of GDNF+1- mice did not differ from WT mice at 4 and 8 months of age. 
At 12 months of age, GDNF/- mice exhibit fewer TH-ir neurons as well as a decrease in 
fiber density compared to age-matched WT mice. This difference is also evident at 20 
months. The loss in the medial SN is greater than the loss in the lateral region of the SN 
(see Figure 4). (Scale bar: 20 J.lm) 
Figure 2-6. Reduction in tota! number of TH-ir neurons in SN of GDNF+1- mice. 
Unbiased stereological cell, counts of midbrain TH-ir neurons. No difference existed in 
the number of TH-ir neurons between GDNF/- and WT mice at 4 and 8 months of age. 
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Between 8 and 12 months, the GDWI- mice displayed a 19.7% decline (p<0.05) in SN 
TH-ir neurons. The number of TH-ir neurons was further decreased 14.3% in 20 month 
old GDWI- mice (p<O.05). Whereas, the WT mice displayed an age-related loss 
between 12 and 20 months of age with a 20% reduction (p<O.Ol). In addition, GDWI-
mice at 12 months had 19% fewer of TH-ir neurons when compared to age-matched WT 
mice (p<O.Ol). The difference in the number of TH-ir neurons between genotypes was 
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Methamphetamine (METH) is a powerfully addictive psychostimulant that causes 
major damage to monoamine-containing axon tenninals in the striatum (Ricuarte et aI., 
1982; Sonsalla et aI. 1992). High doses of METH have repeatedly been shown to cause 
deleterious effects on monoaminergic systems in rodents and primates, including 
decreases in brain levels of dopamine (DA) and serotonin (5-HT), as well as their 
synthetic enzymes, tyrosine and tryptophan hydroxylase, respectively (Hotchkiss and 
Gibb, 1980; Wagner et aI., 1980; Bakhit et aI., 1981; Davidson et aI., 2001). As a 
substrate for monoamine transporters, METH is transported into DAergic terminals, 
causing increased cytosolic DA release and ultimately, DA depletion (for review, see 
Kita et aI., 2003). Even though the underlying mechanisms are not completely 
understood, METH-induced hyperthennia (Bowyer et aI. 1992; Q'Callahan and Miller, 
1994), glutamate excitoxicity (Sonsalla et al. 1986, 1992; Mark et aI., 2004), increased 
production of reactive oxygen species (O'Dell et aI., 1991; Yamamoto and Zhu, 1998; 
LaVoie and Hastings, 1999), and microglia activation (LaVoie et aI., 2004) all contribute 
to the toxic effects of METH on striatal DA terminals. METH abuse is on the rise in the 
USA among young people and evidence is accumulating that the effects of METH abuse 
on DA and 5-HT are prolonged. Even after protracted abstinence, DAT showed only a 
20% recovery in former METH abusers, who also demonstrated slower motor speed and 
deficits in verbal learning (Volkow et aI., 2001a; 2001b). 
Glial cell line-derived neurotrophic factor, (GDNF) , a member of the 
.. 
transforming growth factor-~ superfamily of neurotrophic factors (Krieglstein et aI., 
1995; Saarma, 2000) is required for the survival, high-affinity DA uptake, and neurite 
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outgrowth of cultured midbrain DAergic neurons (Lin et aI., 1993). GDNF also promotes 
recovery of behavior and morphology in rodent and nonhuman primate models of 
Parkinson's disease (PD) , including 6-hydroxydopamine, MPTP, and METH 
(Bowenkamp et aI., 1995; Gash et aI., 1996; Lindner et aI., 1995; Mandel et aI., 1997; 
Kordower et aI., 2000; Cass et aI., 1999, 1996; Melaga et aI., 2000). Importantly, GDNF 
is decreased in the SN of PD patients (Jenner and Olanow, 1998) and also in normal aged 
rodents (Yurek and Fletcher-Turner, 2001) suggesting its involvement in motor 
dysfunction and DA neuron degeneration. 
A GDNF knockout mouse model was first used to explore the role of GDNF in 
fetal and early postnatal development. Whereas prenatal development of mesencephalic 
DA neurons is not dependent on GDNF (Moore et aI., 1996; Pichel et aI., 1996; Sanchez 
et aI., 1996), postnatal maturation of DA neurons is (Granholm et aI., 2000). Further, at 
12 months of age, GDWI- mice display fewer TH-positive neurons in the SN and less 
motor activity than WT mice, as previously described in Chapter 2. We propose that this 
genetic predisposition may increase the vulnerability of DA neurons when mice are 
presented with aa environmental toxin like METR. Therefore in this study, we tested the 
hypothesis that a partial deletion of GDNF would cause an exacerbation of METH-
induced DAergic toxicity during aging. 
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MA TERIALS AND METHODS 
Experimental design. GDNF+1- and WT mice were injected with METH (10 mg/kg, i.p., 
4 times at 2 hr intervals) or saline (0.2 ml 0.9% NaCI, i.p. 4 times at 2 hr intervals) at 2.5 
months of age. Rectal temperatures were recorded after each injection and motor activity 
after the first and fourth injections. In addition, motor activity was recorded at several 
intervals from 3-12 months of age before the mice were perfused and the brains were 
sectioned for immunocytochemical detection of tyrosine hydroxyalse (TH) and 
microglial activation. Separate groups of mice were used for measurements of METH 
concentration, DAT protein and activity levels, and DA, DOPAC, and 5-HT tissue levels 
in the striatum. 
Animals. See Chapter II. 
Body temperature measurements. Rectal temperature was measured prior to the first 
injection and then 20 minutes after each i.p. injection with a TH-5 Thermalert Monitor 
Thermometer (Physitemp Instruments, Inc., Clinton, NJ, USA) by holding each mouse at 
the base of the tail and inserting a probe (RET-3) 2.0 em past the rectum and into the 
colon until a rectal temperature was maintained for 3 s. Body temperature was analyzed 
by a repeated measures ANOV A followed by a Scheffe multiple comparison test when a 
main effect was found. 
Locomotor testing. GDWI - anc! WT mice were tested after the 1st and 4th injections of 
either saline or 10 mg/kg :METH, two weeks post-injection, and then at various ages (6, 
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9, and 12 months of age) to evaluate the effects of a partial GDNF deletion in 
combination with a toxic regimen of METH on motor activity at intervals throughout the 
first year of life. Locomotor activity (total distance traveled) was assessed in a Digiscan 
Animal Activity Monitor system for twenty minutes (Omnitech Electronics Model 
RXYZCM(8) TAO, Columbus, DH). The details of the apparatus have been described 
previously (Halberda et aI., 1997). On the day of testing, the mice were transferred from 
the animal colony into the laboratory in groups of six and tested in a darkened 
environment. Data were collected in one minute intervals for 20 minutes at the same 
time of day (8am to 12pm) for each test period. The data were analyzed by a repeated 
measures ANDV A followed by a Scheffe multiple comparison test when a significant 
main effect was found. 
Striatal METH concentrations. Striatal tissue (9-31 mg) from 5 wildtype and 7 GDNF+/-
mice, age 2.5 months, was analyzed for METH concentrations 30 minutes after the last of 
4 METH injections using gas chromatography-mass spectrometry (GC-MS) and 
performed by Dr. Kennerly Patrick in the Dept. of Phamaceutical Sciences at MUSC. 
This novel microsample method utilized negative ion chemical ionization (NICI)-selected 
ion monitoring of ions 275 amu (derivatized :rvIETH minus HF) and 283 amu (derivatized 
D9-:rvIETH minus DF) .. Samples were extracted by a modification of the process used by 
Johnson-Davis et al. (2004). Frozen striatal tissue was thawed and suspended in distilled 
water, fortified with 100 ng D9-METH (Cerilliant, Round Rock, TX) as an internal 
standard, homogenized (Pol ytron " sonicated, alkalinized with conc NH40H (0.1 mL), 
then extracted with butyl chloride:acetonitrile (4: 1). After centrifugation, the organic 
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phase was transferred to a 4 mL silanized vial fit with a teflon lined screw-cap and 
pentafluoropropionic anhydride (PFP A, 40 uL; Aldrich) was added with vortexing to 
generate acid in situ for trapping METH as the non-volatile salt. After 10 minutes, a 
gentle stream of nitrogen was used to evaporate the sample to dryness and again PFPA 
(50 uL) was added, followed by capping and derivatization at 42°C for 30 minutes. The 
sample was cooled to 25°C, evaporated to dryness again under nitrogen, then the residue 
was dissolved with vortexing in heptane (50 uL) and transferred to a silanized microvial 
insert for 2 IJ.L GC autoinjections. All GC-MS analyses utilized an Agilent Model 5973N 
GC-MS. Chromatographic separations were on a 30 m x 0.25 mm, 0.251J.m film 
thickness 5% phenyldimethylsilicone fused-silica column (DB-5 J. & W. Scientific, 
Folsom, CA, U.S.A.) held at 125 C for 1.5 min, then ramped to 280 C at 20 C / min and 
held for 1.5 min for a total run time of 10.25 min. The injector port was operated at 
240°C. The helium carrier gas linear velocity was 40-50 cm/s. Calibrator samples used 
blank mouse brain tissue (25 mg) spiked with METH (Cerilliant) and processed in 
parallel with the unknowns to yield a linear standard plot (r = 0.9996). The GC-MS 
method was found to be highly sensitive and yielded well resolved ion chromatograms 
devoid of chemical interferences (see Figure 5A). The data were analyzed by a two-tailed 
Student's t-test. 
Synaptosome Preparation. Mice were decapitated, and the striatum was immediately 
homogenized in 10 volumes (w/v) of cold 0.32 M sucrose. The crude synaptosomal 
pellet (P2 fraction) was further purified as previously described (Samuvel et aI., 2005). 
The purified synaptosomes were suspended in regular KRH buffer saturated with 95% 
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0 2/5% CO2. Protein concentration was determined by a DC protein assay (BioRad) using 
bovine serum albumin as the standard. 
DA Uptake. 10-20 Jlg of purified synaptosomes were incubated in 250 JlI of assay buffer 
containing 0.1 mM ascorbic acid, 0.1 mM pargyline and 20 nM [3H]DA for 3 min. as 
described previously (Samuvel et aI., 2005). Nonspecific [3H]DA uptake was defined as 
the accumulation in the presence of 100 JlM cocaine and was subtracted from total 
uptake. Uptake was terminated by addition of 3 ml ice-cold stop buffer (phosphate 
buffered saline (PBS) containing 100 JlM nomifensine) followed by rapid filtration over 
0.3% polyethyleneimine-coated GF-B filters using a Brandel Cell Harvester. Filters were 
washed rapidly with 5 mL cold stop buffer and radioactivity bound to the filter was 
counted by liquid scintillation spectrometry. All uptake assays were performed in 
triplicate and mean values of specific uptake ± S.E.M from at least three separate 
experiments were determined. The data were analyzed using a two-tailed Student's t-test. 
DAT Immunoblotting. DA T immunoblotting was performed on detergent extracts of 
synaptosomes as described previously using an affinity purified DAT-specific antibody 
raised as described previously (Samuvel et aI., 2005). Protein samples were separated 
using 4-15% linear gradient SDS-PAGE, transferred to a polyvinylidene difluoride 
membrane and probed with the DAT antibody as indicated in the figure legends. 
Immunoreactive bands were vi~ualized by EeL plus reagent. Band densities were 
quantified by scanning and analyzed using NIH Image software. The data were analyzed 
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using a Student's t-test. The DAT activity assays were performed by Dr. Sammanda 
Ramamoorthy. 
Immunohistochemistry. At 3 and 12 months of age, mIce were anesthetized with 
halothane and perfused transcardially with saline followed by 4% paraformaldehyde in 
phosphate buffer (O.IM, pH 7.4). The brains were removed, postfixed in 4% 
paraformaldehyde for 24 hrs, and then transferred to 30% sucrose in O.IM PBS for at 
least 24 hrs before sectioning for histochemical analysis. The striatum and midbrain were 
sectioned on a cryostat (Microm, Zeiss, Thornwood, NY, USA) at 45 Jlm. Sections 
through the striatum and SN were processed for free-floating immunohistochemistry 
using a rabbit polyclonal antibody against TH (1 :5000 Pel-Freeze Biologicals, Inc., 
Roger, AZ, USA) or a rat polyclonal antibody against CD45 (1:1000 Serotec North 
America, Raleigh, NC, USA). TH and CD45 immunohistochemistry was performed 
using the avidin-biotin-immunoperoxidase method (Choe and McGinty 2000). Briefly, 
after a 5 min. pretreatment with 2% Triton-X to allow penetration Jnto the tissue, a subset 
of sections from each mouse was incubated simultaneously in the primary antisera 
against TH or CD45 for 24 hrs at 4°C. The sections were then rinsed and incubated for 
Ihr in biotin-conjugated goat anti-rabbit (for TH) or biotin-conjugated rabbit anti-rat (for 
CD45) IgO, rinsed, and incubated for Ih in avidin-biotin-peroxidase reagents (Elite 
Vectastain kit, Vector Labs, Burlingame, CA). The reaction is developed by staining with 
VIP (Vector Labs, Burlingame, CA) to yield a purple reaction product. Each of the above 
steps is separated by 3 x 10 min. washes in PBS. Sections were mounted on glass slides 
and coverslipped with DPX. 
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Immunohistochemical semi-quantitation. Analysis was performed using the NllI Image 
program as described previously (Choe and McGinty, 2000). Briefly, background was 
subtracted and the LUT scale was adjusted using density slicing. This approach captures 
all labeled profiles above a threshold density and interactively discriminates them from 
density values below the threshold. The software then automatically measures the mean 
optical density and # of pixels per area of the extracted profiles in the selected medial or 
lateral striatal regions. Two parameters were obtained from this procedure: the area 
covered by the specific profile population (field area), and the mean density of the 
specific profiles. Total immunoreactivity (integrated density) is obtained by mUltiplying 
the field area times the mean density value. The semi-quantified data were evaluated by 
a 2x2 ANDV A followed by a Scheffe multiple comparison test when a significant main 
effect was found. 
Stereological cell counts. Quantitative estimates of the total number of TH-ir neurons in 
the SN were achieved using an unbiased, stereological cell counting method (Gundersen 
and Jensen, 1987; Granholm et aI., 2002). Briefly, the optical fractionator system 
consists of a computer assisted image analysis system including a Nikon Eclipse E-600 
microscope hard-coupled to a Prior H128 computer controlled x-y-z motorized stage, an 
Olympus-750 video camera system, a Micron Pentium ITI 450 computer, and 
stereological software (Stereoinvestigator®, MicroBrightField Inc.; Colchester, VT). 
The SN was outlined under low magnification (lOX) on every 3rd section through the 
rostro-caudal extent of the midbrain, and the outlined region was measured with a 
systematic random design of disector counting frames (100 x 100 urn). Actual mounted 
section thickness was found to be 35-37 J.Lm, and a 2 Jlm guard zone was set for the top 
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and bottom of each section. A 40X objective lens with a 1.4 numerical aperture was used 
to count cells within the counting frames. Effects were assessed by a 2x2 ANDV A 
followed by a Scheffe multiple comparison test when a significant main effect was found. 
Measurement of 5-HT, DA and DOPAC in brain tissue. At 3 and 12 months of age, mice 
were euthanized and the unilateral striatum was dissected and frozen at -80°C. The 
unilateral tissue samples were placed in 300 Jll of mobile phase containing 0.2 JlM 
isoproterenol as an internal standard, sonicated and centrifuged (2 min. at 13000 rpm). 
The protein content in the resulting pellet was measured using the Bradford assay. The 
concentration of DA and 5-HT and metabolites in the supernatant was measured by 
injecting 5 JlI of the supernatant into the high performance liquid chromatography 
(HPLC). An ESA pump (model 582, ESA, Chelmsford, MA, USA) was used to deliver 
0.5 mllmin of mobile phase (0.1 M trichloroacetic acid, 0.01 M sodium acetate, 0.1 mM 
EDTA and 16% MetOH, pH= 4.1) to a reversed phase column (ESA HR-BO). After 
separation from the column, the biogenic amines were oxidized/reduced using 
coulometric detection (Coulochem II; ESA Inc.). Three electrodes were used: a guard 
cell (+0.40 V), a reduction analytical electrode (E1, -0.15 V), and an oxidation analytical 
electrode (E2, +0.325 V). The peak areas were measured with an ESA 501 
Chromatography Data System and the values were compared with an external standard 
curve for quantification. The final data were evaluated as picomoles per milligram of 
protein. Quantification was evaluated by a 2x2 ANDV A followed by a Scheffe multiple 
comparison test. 
RESULTS 
METH has similar effects on body temperature and locomotor activity In "WT and 
GDNpl- mice 
Bod y temperatures of the four groups did not differ prior to or after the 1 st 
injection (Tl) whether injected with METH or saline (Figure 3-1A). However, after 
injections 2-4 (T2-4), the METH-treated mice exhibited a significant increase in body 
temperature that was similar in both genotypes (p<O.05). The saline- treated mice 
continued to have stable temperatures similar to basal temperatures taken before the 
injection regimen began. 
Regardless of genotype, the first injection of METH increased motor activity as 
compared to saline-injected mice (Figure 3-1B). In contrast, METH-treated mice 
exhibited decreased motor activity compared to saline-treated mice after the fourth 
injection (Figure 3-1C). Two weeks post-injection (3 months of age), the motor activity 
of the METH treated mice was similar to that of saline-treated mice, regardless of 
genotype (Figure 3-1D). 
METH exacerbates striatal TH-ir depletion and nigral microglial activation in 3 month 
old GDNpl- vs. WT mice 
Two weeks following the injections, integrated density revealed that TH-ir levels 
in the dorsolateral striatum of saline injected mice were similar for the two genotypes. In 
contrast, TH-ir levels in the dorsomedial striatum of saline injected GDNF/- mice were 
68% lower than that of WT mice treated with saline (Figure 3-2A, B, E). This reduction 
in TH-ir for GDNF/- compared to WT mice was due to fewer pixels per area rather than 
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a difference in the mean density, suggesting fewer TH-positive terminals but the same 
amount of TH per terminal in GDWI- mice (Table 3-1). Two weeks after the METH 
injections, TH-ir in the lateral striatum was reduced to 97% and 99% that of saline 
controls for WT and GDNF+1- mice, respectively (Figure 3-2C, D and E-left). This 
decrease was due to a combined loss in the number of pixels per area and mean density in 
both genotypes (Table 3-1). In contrast, in the medial striatum, METH produced a 
significantly greater decrease in TH-ir for GDWI- (89%) than for WT (55%) mice 
(Figure 3-2C, D and E-right). This decrease was due to fewer pixels per area for the 
METH-treated, WT mice, suggesting fewer axon terminals. For METH-treated, GDWI-
mice, the decrease was due to a combined decrease of pixels per area and mean density in 
(Table 3-1). In contrast to these effects, when assessed at 3 months of age, stereological 
cell counts indicated no difference amoung the four groups in the number of TH-ir 
neurons (data not shown). 
The microglial response in the striatum and SN to the toxic METH binge is 
illustrated in Figure 3-3. Activated microglia are characterized by an ameboid 
morphology with shorter but thicker processes than resting microglia. Microglial 
activation in the SN was greater for GDWI- than for WT mice treated with saline 
(Figure 3-3A, B and I). Further, microglial activation was greater in METH-treated than 
saline-treated WT mice (Figure 3-3A, C, I), and the activation was greater after METH in 
GDNF/- than WT mice (Figure 3-3C, D, I). In contrast to these effects in SN, microglial 
activation in the striatum did not differ among the genotypes or treatment groups at this 
age (Figure 3-3 E-H, J). 
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METH depletes DA and DOPAC levels in 3 month old GDNpl- and WT mice 
DA and nop AC concentrations in striatum were significantly higher in 
GDNF+/- than WT mice treated with saline (Figure 3-4A, B). However, the DAIDOPAC 
ratio and 5-HTconcentrations did not differ according to genotype (Figure 3-4C and D). 
Two weeks after drug treatment, DA and nop AC concentrations were reduced to similar 
levels in l\1ETH-treated GDWI- and WT mice (Figure 3-4A and B) but the proportional 
decrease was greater for GnW'- (DA 88%; DOPAC 75%) than for WT mice (DA 76%; 
DOPAC 60%). The DAIDOPAC ratios were lower in :METH-treated than saline-treated 
mice but did not differ by genotype (Figure 3-4C). :METH decreased striatal 5-HT less 
than DA and the effect was similar in both genotypes (31 % in WT and 38% in GDWI-
Figure 3-4D). This effect was significant for both genotypes (p<O.05). 
Striatal METH concentrations do not differ in GDNpl- and WT mice 
To investigate whether differences between METH concentrations in GDNF+1-
and WT mice were pertinent to the underlying toxicology, the concentration of METH in 
the striatum was determined 30 min after the last of four :rvtETH injections in a separate 
set of mice. Figure 3-5A illustrates a representative GC-MS-NICI selected ion monitoring 
chromatogram of pentafloroupropionyl derivatized METH extracted from a METH 
treated mouse striatal microsample. The NICI fragments monitored resulted from loss of 
HF from the drug (ion 275; t R = 4.32 min) and DF from the nonadeuterated internal 
standard (ion 283; t R = 4.28 min). Note that the customary deuterium isotope effect 
reduced the retension time of th~. internal standard by 0.04 minutes relative to that of the 
analyte. When this method was applied to striatal tissue collected 30 minutes after the 
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last of four METH injections, no significant difference in METH concentrations was 
found between genotypes (Figure 3-5B). 
DAT activity, but not protein, levels are higher in untreated GDNpl- vs. WT mice 
DAT activity was significantly higher in striatal synaptosomes from 3-month-old 
untreated GDWI- vs. WT mice (Figure 3-6). In contrast, there was no difference in 
DAT protein levels in the whole striatum for the two genotypes (Figure 3-6 inset). 
GDNF/- mice were not available for DAT activity measurements after METH treatment. 
METH effects on motor activity with aging differ in GDNpl- vs. WT mice 
Another cohort of GDWI- and WT mice was used to examine the long-term 
effects of METH in the two genotypes. Mice were injected with either saline or METH 
(10mglkg x 4 i.p., every 2 hrs, n=8 per group) at 2.5 months of age as in the earlier 
experiment. Locomotor activity and body temperatures for all groups were similar to 
those reported in Experiment 1. In this follow-up experiment, locomotor activity was 
assessed for 20 minutes every 3 months until 12 months of age. At 6 months of age, 
locomotor activity did not differ among the four groups (data not shown). At 9 months of 
age, however, the mice previously treated with METH, regardless of genotype, displayed 
significantly less locomotor activity than the saline-treated mice (Figure 3-7 A). 
Interestingly, at 12 months of age, locomotor activity of saline control GDNF/- mice was 
less than that of similar aged WT saline controls. Moreover, activity of GDNF/- mice 
exposed to METH at 2.5 rno of age was less than WT mice with similar METH exposure 
(Figure 3-7B). 
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Long-term neurochemical effects are exacerbated in METH-treated GDNpl- vs. WT 
mice 
Striatal TH-ir of 12 month old GDWI- and WT mice after administration of a 
toxic regimen of :METH at 2.5 months of age is illustrated in Figure 3-8. Unlike the TH-
ir data from the 3-month-old age groups, the density of TH-ir in the striatum of 12-
month-old mice did not differ along a medial/lateral dimension. For this age group, 
however, TH-ir in both striatal regions was significantly lower for saline-treated GDWI-
than WT mice (Figure 3-8 E). In the lateral striatum, TH-ir in each METH-treated group 
was significantly less than in the respective saline-treated group (Figure 3-8 A, B vs. C, D 
and E). In the medial striatum, TH-ir was significantly less in WT mice treated with 
METH than those treated with saline (Fig 3-8 E) whereas TH-ir did not differ for 
GDNF/- mice treated with :METH vs. saline. Analysis of the components of integrated 
density revealed more significant decreases in mean density than in area at this age than 
noted at the younger age (Table 3-2). However, both area and mean density contributed 
to the significant differences in integrated density in the medial striatum (Fig 3-8 E). In 
contrast to 3 months of age, at 12 months, saline-treated GDWI- mice had significantly 
fewer TH-positive neurons in the substantia nigra than saline-treated WT mice (Figure 3-
9). However, the number of TH-positive neurons did not differ between saline-treated 
and METH-treated mice. Furth ennore , there were no differences in CD45-ir in the 
striatum or SN among the groups (data not shown). 
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METH-induced depletion of DA and DOPAC levels is exacerbated in 12-month-old 
GDNrl - vs. WT mice 
Saline-treated GDNF+1- mIce had lower DA and DOPAC concentrations in 
striatum than was observed for saline-treated WT mice at 12 month of age; however, the 
DAIDOPAC ratios and 5-HT levels did not differ according to genotype (Figure 3-10 A-
D). All METH-treated mice, regardless of genotype, had significantly lower levels of 
these markers compared to saline-treated mice (Figure 3-10 A-D) but not as low as mice 
2 weeks after METH. Interestingly, METH-treated GDWI- mice had significantly lower 
levels of DA (67%) and DOPAC (38%), but similar DAIDOPAC ratios and 5-HT levels, 
compared to METH-treated WT mice (Figure 3-10 A-D). 
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DISCUSSION 
METH-induced depletion of TH-ir was exacerbated initially and recovery was 
slightly less over time in the striatum of GDNF/~ vs. WT mice. Further, there was a 
proportionally greater loss in DA and DOPAC in the striatum of 3-month-old GDNF/~ 
mice than in WT mice and recovery at 12 months was less in GDNF/- vs. WT mice. 
Finally, motor responses to METH were not different in GDNpl- and WT mice during 
treatment, or at 2 weeks or 9 months post treatment. However, motor activity at 12 
months of age was significantly less for GDNF/- mice than for WT mice that had been 
exposed to :METH as young adults in spite of no genotypic differences in the 
pharmacokinetics or hyperthermic response to the JvlETH binge.' DAT activity in 
synaptosomes processed from striatal tissue of 3-month-old untreated GDNF/- mice was 
greater than in untreated WT mice, suggesting that more METH may be taken up into 
striatal terminals of GDNF/- mice than in WT mice, thus exacerbating DA terminal 
damage. 
METH induces long-term behavioral effects 
In the present study, motor activity deficits did not occur until GDNF/- and WT 
mice, previously treated with METH, reached 9 months of age. Further, it wasn't until 
12 months of age that GDNF/- mice displayed less activity than WT mice, whether they 
were previously treated with METH or not. In an earlier study (Chapter 2), a reduction in 
motor activity for GDNF/- mice was first detected at 12 months of age. The present 
experiment indicates that the dec~jne in motor activity associated with aging was greater 
for :METH-exposed GDNF/- than WT mice. Thus, it is reasonable to speculate that 
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young adults who binge on high doses of METH may experience deleterious motor 
consequences as they age. 
Untreated GDNpl- mice have higher DA and DOPAC levels, and more DAT activity, but 
less TH-ir, in the striatum than wr mice 
. Young untreated GDWI- mice have less TH-ir innervation in the medial striatum 
than WT mice but no difference in SN TH-ir cell bodies, suggesting a role for GDNF in 
the development and/or maintenance of DAergic axon tenninals. This result is consistent 
with evidence that GDNF mediates postnatal DAergic axon sprouting (Bachelor et aI., 
2000; Rosenbald et aI., 1998; Kirik et aI., 2000; Lindner et aI., 1995). This difference 
could be due to less TH per axon or fewer axons per area. In fact, the mean density of 
TH-ir did not differ but the number of pixels per area did, suggesting that there were 
fewer axons per area in the GDNP/6 mice but not less TH per axon, (i.e., DA synthesis 
per axon was not lower in GDWI- vs. WT mice). In contrast, untreated GDWI- mice 
had greater DA and DOPAC concentrations and increased synaptosomal DAT activity 
but no difference in the striatal DAIDOPAC ratio or in TH-ir cell number in the SN. This 
combination of results is suggestive of increased DA uptake and DA accumulation in the 
surviving axons without increased synthesis or turnover. GDWI- mice, in mid-life (12 
months), demonstrated that the medial striatum contained less TH-ir per area, and both 
striatal areas had less TH-ir mean density and less DA and DOPAC than age-matched 
WT mice, a combination suggesting that DA uptake is unable to compensate for reduced 
synthesis later in life. Fewer TH::ir neurons in the SN of 12-month-old GDWI- mice vs. 
WT mice may also contribute to this profile. In the present study, METH treatment 
( 
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caused a mark reduction in striatal 5-HT tissue levels. The absence of differences 
between GDNF'- and WT mice, however, is indicative of no relationship between GDNF 
and the serotonergic system. These data suggest that GDNF plays an important role in 
the maintenance, survival, and function of DAergic axons during aging. 
GDNpl- mice displayed prolonged DAergic damage in response to METH 
In comparison to WT mice, GDNF'- mice treated with METH displayed greater 
detrimental effects at 3 and 12 months of age. The clearest example is the more profound 
~TH-induced depletion of TH-ir in GDNF'- mice than in WT mice. Two weeks after 
~TH treatment at 3 months of age, the TH-innervated area, but not the mean density, in 
the medial striatum was lower in GDNF'- vs. WT mice, suggesting a decrease in the 
number ofaxons but not the amount of TH per remaining axon in the young adult mice. 
At 12 months of age, middle age for mice, the deficit in TH-ir was in both the area of 
innervation and the mean density of the TH signal. Similarly, at this age, DA and 
DOPAC were reduced in GDNF'- compared to WT mice, again suggesting less DA 
synthesis in fewer axons for the METH-treated GDNF'- mice. At 12 months of age, 5-
HT levels in the striatum were lower in METH compared to saline treated mice, an effect 
that tended to be enhanced in GDNF'- mice, suggesting a possible role for GDNF in 
serotonergic innervation later in life. It is important to note that in spite of an 88% 
reduction in striatal tissue DA levels noted for GDNF'- mice treated with METH at 3 
months of age (2 weeks post-injection), no loss of TH-positive neurons in the substantia 
nigra or motor activity impairmel)ts were noted under the conditions of this experiment. 
This discrepancy may suggest that sufficient striatal DA innervation survived for the 
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mice to perfonn basic locomotor functions although several reports suggest that DA cells 
loss of 80% or more is associated with motor impairment after 6-hydroxydopamine 
lesions (Anden et aI., 1966; Hudson et aI., 1993; Kirik et aI., 1998). Another possible 
reason for the absence of motor deficits in the 3 month old mice is that DA innervation of 
the nucleus accumbens, a related brain structure that mediates locomotor activity, was 
unaffected by the treatment (Swanson and Kalivas, 2000, Swanson et aI., 1997). It may 
also be possible to differentiate METH treated animals from saline treated controls 
through the use of operant behavioral techniques as previously described (Fischman and 
Schuster, 1974, 1977). In addition, experiments assessing 1v1ETH effects on behavior 
have demonstrated that rats with a DA depletion had a significantly blunted response to 
the activity-enhancing effects of METH or apomorphine and showed supersensitivity to 
the activity-decreasing effects of haloperidol (Bittner et aI., 1981). 
Possible mechanisms for exacerbated METH toxicity in GDNr/~ vs. WT mice 
METH-induced hyperthermia and striatal :rv1ETH concentrations did not differ 
between genotypes; therefore these parameters could not contribute to the exacerbated 
DA toxicity in the GDWI - mice. Alternatively, DAT activity, which is critically 
involved in inward transport of METH with concomitant outward transport of DA (Liang 
and Rutledge, 1982), is an important determinant of METH neurotoxicity and a likely 
candidate for the drug's enhanced neurotoxicity observed for GDNpl- mice. :METH-
induced reductions in striatal DA parameters are blocked by DAT antagonists (Schmidt 
and Gibb, 1985; Marek et aI., 1990; Pu et aI., 1994). This protective action can occur 
even if the DA T blocker is administered as long as 8 hrs after the neurotoxic METH 
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treatment (Marek et aI., 1990). These data suggest that DAT activity contributes to a 
sequence of events that occur hours after METH treatment and is required for toxicity to 
be expressed. The critical role of DAT in METH neurotoxicity is further supported by the 
observation of Caron and coworkers that METH toxicity is completely absent in DAT 
knockout mice (Fumagalli et aI., 1998). In the present study, mice with a partial 
depletion of GDNF displayed higher DAT activity levels at 3 months of age. This 
increase in activity suggests that the GDWI- mice were able to take up more METH into 
striatal DA terminals resulting in increase DA neural toxicity. Future studies will be 
conducted to assess other possible mechanisms that may be involved in the increased 
METH-induced DAergic toxicity seen in mice with a partial depletion of GDNF, ie. 
cellular oxidative stress, dysregulation of apoptotic pathways, and glutamate 
excitotoxicity (Cadet and Brannock 1998; Hirata et aI. 1997, 1996; Imam and Ali 2001; 
Jayanthi et aI. 2004; Sonsalla et aI., 1986, 1991; Mark et aI., 2004). 
In conclusion, the present study suggests that a life-long reduction of GDNF and 
exposure to toxic doses of METH during young adulthood independently lead to long-
term alterations in the nigrostriatal DAergic system. Furthermore, in combination, the 
two factors result in an exacerbation of DAergic damage during aging, a dual-hit 
hypothesis of neurodegeneration. Thus a genetic disruption of neurotrophic support 
coupled with a Daergic neurotoxin during maturation gives rise to enhanced Daergic 
vulnerability that leads to deficits in neuronal functioning during aging. 
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FIGURE LEGENDS 
Figure 3-1. METH-induced hyperthermia and locomotor activity did not differ 
between GDNF+!- and WT mice. (A) METH treated mice exhibited a significant 
increase in body temperature when compared to saline treated mice (p<O.05). However, 
GDNF/- mice did not differ in the hyperthermic response to METH when compared to 
WT mice. (B) After the 1 st METH injection, regardless of genotype, the mice were 
hyperactive compared to saline treated mice (p<O.OOl). However, after the 4th injection 
(C) the mice treated with METH, regardless of genotype, were hypoactive when 
compared to saline treated mice (p<O.OOl). Two weeks post METH binge (D), no 
differences existed in locomotor activity between the four groups. N=5 per group 
(*p=O.05, ***p=O.OOl). 
Figure 3-2. GDNF+!- mice treated with METH demonstrate a greater loss of tyrosine 
hydroxylase (TH) immunostaining than wildtype mice two weeks after the METH 
binge. TH-ir of coronal sections of the striatum from (A) saline-treated WT mice, (B) 
saline-treated GDNP'- mice, (C) METH-treated WT mice, and (D) METH-treated 
GDNF/- mice. At 3 months of age, 2 weeks after the METH binge, METH-induced a 
similar TH-ir depletion in the lateral striatum of GDNF/- and WT mice (C, D) when 
compared to saline treated mice (p<O.OOl) and a significantly greater depletion in the 
medial striatum of GDNF'- than WT mice (p<O.OOl). (E) Quantitation of the average 
integrated density between the four treatment groups demonstrated that no differences 
existed in the lateral region of tne striatum between the GDNF+1- and WT mice treated 
with saline. In the medial region, the GDNF+/- mice displayed less TH-ir and the 
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GDW'- mice treated with METH had a greater TH-ir depletion than the WT mice 
treated with METH. (***p=O.OOl). 
Figure 3-3. The GDNF*'- mice treated with METH had a greater inflammatory 
response in the SN two weeks post injection. CD45 immunohistochemistry illustrating 
activated microglia in the SN (A-D) and striatum (E-H) of (A, E) saline-treated WT mice, 
(B, F) saline-treated GDNF'- mice, (C, G) METH-treated WT mice, and (D, H) METH-
treated GDNF'- mice. (I, J) Quantitation of the average integrated density of CD45 
immunoreactivity in the SN and striatum, respectively. Saline-treated GDNF/- mice had 
more activated microglia in the SN when compared to saline-treated WT mice (p<O.OOl). 
:METH induced an increase in activated microglia in WT mice when compared to saline-
treated mice (p<0.05). However, METH treatment caused a significantly greater increase 
in microglia activation in the SN of GDNF'- mice two weeks after injection when 
compared to either saline-treated GDNF+/- mice or METH-treated WT mice (p<O.OOl). 
N=5 per group (*p=O.05, ***p=O.OOl). 
Figure 3-4. METH treatment resulted in a significant reduction in striatal tissue 
levels of DA, DOPAC, and 5-HT. At 3 months of age, GDNF/- mice had higher tissue 
levels of (A) DA and (B) DOPAC compared to WT mice (p<O.05), but there was no 
difference in (D) 5-HT tissue levels. :METH treatment caused a significant reduction in 
DA, DOPAC, and 5-HT tissue levels in WT mice (p<O.OOl). However, the reduction in 
DA and DOPAC was proportionally greater in GDNF/- mice vs. WT mice treated with 
METH (p<O.OOl). (C) The DAIDOPAC ratio was not different between the genotypes 
treated with saline, but METH treatment reduced the ratio similarly in both genotypes 
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(p<O.05). (D) 5-HT tissue levels were similar in saline-treated GDNF+1- and WT mice 
and were decreased to the same extent by rvlliTH. N=5 per group (*p=O.05, ***p=O.OOI). 
Figure 3-5. The concentration of METH in the striatum was not different between 
GDNF+I-and WT mice. (A) GC-MS-NICI selected ion monitoring chromatogram of 
1vIETH (top) and the deuterated internal standard (bottom) extracted from a mouse striatal 
tissue microsample. (B) :METH concentration (uglgm tissue weight) in the striatum was 
not different in WT and GDWI- mice 30 minutes after the 4th injection of a :METH binge 
(p=O.47) N=5 per group. 
Figure 3-6. Three-month-old GDNF+1- mice have increased DAT activity, but not 
DA T protein, levels in the striatum compared to WT mice. Untreated GDWI- mice 
express significantly more DAT activity in striatal synaptasomes compared to WT mice 
(p<O.05). However, striatal DAT protein level does not differ between the two genotypes 
when assessed by western blot. N= 6 per group (*p=0.05). 
Figure 3-7. METH treatment has long-term effects on locomotor activity. (A) At 9 
months of age, mice treated with l\1ETH, regardless of genotype, had less locomotor 
activity than saline-treated mice (p<0.05). (B) At 12 months of age, GDWI- displayed 
less motor activity than WT mice (p<O.05). METH-treated mice exhibited less motor 
activity than saline-treated mice (p<O.05); however, this effect was exacerbated in 
METH-treated GDNF/-mice. N=8 per group (*p=O.05). 
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Figure 3·8. METH-induced TH-ir depletion is greater in lateral striatum of 12 
month old GDNF+/- mice. A-D Photomicrographs of coronal hemi-sections through the 
striatum of 12 mo old mice stained with TH antiserum. (A) WT mice treated with saline, 
(B) GDNF'- mice treated with saline, (C) WT mice treated with METH, (D) GDNF'-
mice treated with METH. (E) Quantification of the integrated density signals of 
immunostained sections demonstrates the reduction of TH-ir in the striatum of GDNP+/-
mice is significantly greater than in WT mice. N=8 per group (*p=O.05). 
Figure 3-9. METH treatment had no effect on the number of SN TH-ir neurons at 
12 months of age. GDNF/- mice have fewer TH-positive neurons in the SN at 12 
months of age than WT mice (p<O.05). l\1ETH treatment did not alter the number of SN 
TH-positive neurons in either genotype. N=8 per group (*p<O.05). 
Figure 3-10. METH-induced reductions in striatal DA, DOPAC, and 5-HT tissue 
levels are still present at 12 months of age. Saline-treated GO NF/- mice had lower 
striatal tissue levels of (A) DA and (B) DOPAC, but not in the (C) DAIDOPAC ratio or 
(0) 5-HT, as compared to WT mice. METH-treated WT mice had lower tissue levels of 
DA, DOPAC, DAIDOPAC, and 5-HT when compared to saline-treated WT mice 
(p<O.05). DA and DOPAC levels were significantly lower in GDNpl- mice vs. WT mice 
treated with METH. N=8 per group (*p=O.05, **p=O.Ol, ***p=O.OOI). 
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Figure 3-2. 
Table 3-1. The Number of Pixels Per Area and Mean Density of TH-ir in the Striatum 
of3 Month Old GDNF+/- and WT Mice Treated with Saline or Meth 
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Genotype Treatment Brain Region A vg. Area ± SE A vg. Mean Density 
±SE 
WI Saline Lateral Striatum 2370.64± 36.38 13S.26±O.61 
Medial Striatum 1639.12± 102.33 133.28±O.71 
GDNF+/- Saline Lateral Striatum 2334.00± 60.34 137.S4±O.67 
Medial Striatum 885.44± 137.52· 132.88±0.56 
WT Meth Lateral Striatum 61.24± 36.02* 1IS.30±8.71 «> 
Medial Striatum 727.52± 81.94w 133.67±0.42 
GDNF+/- Meth Lateral Striatum 2.64± 0.49" 9S.35±12.15@$ 
Medial Striatum 95.04± 20.S7#t IIS.43±8.71 ~f 
Avg. Area=*, 'V p<O.05 vs. WT Saline Medial Str, ip<O.05 vs. WT Saline Lateral Str, 
,»<0.0001 vs. GDNF+/- Saline Lateral Str, #p<O.OOOl vs. GDNF+/- Saline Medial Str, 
tp<O.OOOl vs. WT Meth Medial Str. 
Avg. Mean Density=oop<0.05 vs. WT Saline Lateral Str, @p<O.OOl vs. GDNF+/-
Saline Lateral Str, ~p<0.05 vs. GDNF+/- Saline Medial Str, $p<O.OS vs. WT Meth 
Lateral Str, /p<O.05 vs. WT Meth Medial Str. 
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CHAPTER IV 
Minocycline Restores Striatal Tyrosine Hydroxylase in GDNF 
Heterozygous Mice But Not in Methamphetamine-treated Mice 
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INTRODUCTION 
Inflammation is an active defense reaction of multi-cellular organisms against 
diverse insults, designed to remove or inactivate noxious agents and to inhibit and reverse 
their detrimental effects. Normally, microglia are in a resting state characterized by 
ramified morphology. However, under subtle changes in their micro-environment or as a 
consequence of pathological changes, they transform into their activated state and display 
an amoeboid morphology (Kreutzberg, 1996). Microglial activation occurs in 
association with various brain injuries (Kato et aI., 2000), including damage common to 
neurological diseases (De Simone et aI., 1995; Banati et aI., 1998; Versijpt et aI., 2003), 
as well as with damage resulting from neurotoxic chemicals often used to model disease 
(Jorgensen et aI., 1993; Scali et aI., 1999; Fiedorowicz et aI., 2001). Microglia perform 
various functions in tissue repair and neural regeneration by releasing trophic factors 
(Nakajima and Kohsaka, 1993). However, activated microglia mainly act as scavenger 
cells and exacerbate degeneration causing an increased release of pro-inflammatory 
molecules such as reactive oxygen species (ROS), interleukin (IL)-I~, tumor necrosis 
factor u (TNFu), and nitric oxide (NO), the overproduction of which is toxic (Kennedy et 
aI., 1997, Hald et a!., 2005). 
Inflammation is also thought to contribute to the supply of neurotrophic factors. 
For example, GDNF is expressed in activated microglia, macrophages and astrocytes of 
the injured eNS (Widenfalk et aI., 2001; Satake et aI., 2000; Wei et aI., 2000; Appel et 
aI., 1997). This expression/excretion of GDNF from activated microglia/macrophages is 
beneficial in the recovery of loco .. motor activity after spinal cord injury and may provide 
neurotrophic support to GDNF-responsive neurons under conditions of bacterial infection 
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and inflammation (Hashimoto et aI., 2005; Appel et aI., 1997). Furthermore, in the 
previous chapter, mice with a partial GDNF deletion (GDWI-) demonstrated more 
microglial activation in the SN than WT mice without any neurotoxic insult. These facts 
suggest that the type of activation determines if microgliaimacrophages produce 
molecules harmful or trophic for neurons. Even though it is not known, optimal 
inflammation induced by properly activated microgliaimacrophages may favor CNS 
nerve regeneration. 
Previous studies demonstrated that METH causes an increase in reactive gliosis 
(Sheng et aI., 1994; Hebert and o'Callaghan, 2000) and microglia activation (Lavoie et 
aI., 2004; Thomas et aI., 2004a, b), as well as induction of certain inflammatory genes, 
including TNFu, cyclooxygenase-2 (COX-2), and thiobarbituric acid (TBA), in the 
striatum (Flora et aI., 2002; Kita et aI., 2000). Similarly, in the previous study (Chapter 
II) in which the toxic effects of METH were assessed, it was discovered that SN 
microglial activation in GDWI- vs. WT mice was greater two weeks after injection. 
These data suggest that activated microglial cells may contribute to neuronal 
degeneration (Langston et aI., 1999). 
Minocycline is a second-generation semi-synthetic antibiotic belonging to the 
tetracycline family and is known to have anti-inflammatory (Tikka et aI., 2001a, b) and 
anti-apoptotic properties (Zhu et aI., 2002; Wang et aI., 2004). The interest in 
minocycline has grown in recent years because it easily crosses the blood-brain barrier 
and exerts powerful protective eff.ects in the CNS. Minocycline treatment has markedly 
reduced neurodegeneration in models of ischemia (Yrjanheikki et aI., 1998; 1999), 
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amyotrophic lateral sclerosis (Zhu et al., 2002; Kriz et aI., 2002), Huntington's disease 
(Chen et aI., 2000; Wang et aI., 2003), and PO (Du et aI., 2000; Wu et aI., 2002). 
Therefore, clinical trials for the possible treatment of PO (Ravina et al., 2003) and 
Huntington's disease (Bonelli et aI., 2003) have been initiated. 
In the present study, minocycline was administered to METH-exposed GoNF/-
mice to determine whether METH-induced striatal dopaminergic damage could be 
prevented by the suppression of microglial activation. 
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MA TERIALS AND METHODS 
Experimental design. GDNF/- and WT mice were injected with METH (10 mg/kg, i.p., 
4 times at 2 hr intervals, Sigma-Aldrich) or saline (0.2 ml 0.9% NaCI, i.p. 4 times at 2 hr 
intervals) at 2.5 months of age. Rectal temperatures were recorded after each injection, 
and motor activity after the first and fourth injections. Starting 24 hrs after the last METH 
injection, GDNF/- and WT mice were injected for 14 days with minocycline 
hydrochloride (45 mg/kg, i.p., MP Biomedicals) or saline (0.2 ml 0.9% NaCI, i.p.). This 
regimen was used based on previous studies from our lab (Hunter et al., 2004; Quintero 
et al., 2006). After the ~4-day minocycline regimen, motor activity was recorded before 
the mice were perfused and the brains were sectioned for immunohistochemical detection 
of TH, microglial activation (CD45), and phospho-p38 MAP Kinase. 
Animals. Refer to Chapter II. 
Body temperature measurements. Refer to Chapter III. 
Locomotor testing. Refer to Chapter III. 
Immunohistochemistry. At 3 months of age, mice were anesthetized with halothane and 
perfused transcardially with saline followed by 4% paraformaldehyde in phosphate buffer 
(O.1M, pH 7.4). The brains were removed, postfixed in paraformaldebyde for 24 hrs, and 
then transferred to 300/0 sucrose in O.lM PBS for at least 24 hrs before sectioning for 
histochemical analysis. The striatum and midbrain were sectioned on a cryostat (Microm, 
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Zeiss, Thornwood, NY, USA) at 40 f..Lm. Sections through the striatum and SN were 
processed for free-floating immunohistochemistry using a rabbit polyclonal antibody 
against TH (1:5000 Pel-Freeze Biologicals), or a rat polyclonal antibody against CD45 
(1:500 Serotec). Sections through the midbrain were stained for a rabbit polyclonal 
antibody against phospho-p38 MAPK (1:500 Chemicon). Immunohistochemistry was 
performed using the avidin-biotin-immunoperoxidase method (Choe and McGinty 2000). 
Briefly, after a 5 min. pretreatment with 2% Triton-X to allow penetration into the tissue, 
a subset of sections from each mouse was incubated simultaneously in the primary 
antisera against TH or CD45 for 24 hrs at 4°C. The sections were then rinsed and 
incubated for Ihr in biotin-conjugated goat anti-rabbit (for TH and phospho-p38 MAPK) 
or biotin-conjugated rabbit anti-rat (for CD45) IgG, rinsed, and incubated for Ihr in 
avidin-biotin-peroxidase reagents (Elite Vectastain kit, Vector Labs, Burlingame, CA). 
The reaction is developed by staining with VIP (Vector Labs, Burlingame, CA) to yield a 
purple reaction product. Each of the above steps is separated by 3 x 10 min. washes in 
PBS. Sections were mounted on glass slides and coverslipped with DPX. 
Immunohistochemical semi-quantitation. Analysis was performed using the NIH Image 
program as described previously (Choe and McGinty, 2000). Briefly, film background 
was subtracted and the LUT scale was adjusted using density slicing. This approach 
captures all labeled profiles above a threshold density and interactively discriminates 
them from density values below the threshold. The software then automatically measures 
the mean optical density and # of pixels per area of the extracted profiles in the selected 
medial or lateral striatal regions. Two parameters were obtained from this procedure: the 
area covered by the specific profile population (field area), and the mean density of the 
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specific profiles. Total immunoreactivity (integrated density) is obtained by multiplying 
the field area times the mean density value. The semi-quantified data were evaluated by 
a 3-way ANOV A followed by a Scheffe multiple comparison test when a significant 
main effect was found. 
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RESULTS 
METH effects on body temperature 
Body temperatures of the four groups did not differ prior to or after the 1 st 
injection (T1) whether injected with METH or saline (Figure 4-1 A). However, after 
injections 2-4 (T2-4), the METH-treated mice exhibited a significant increase in body 
temperature which was similar in both genotypes (p<O.05). The saline-treated mice 
continued to have stable temperatures similar to basal temperatures taken before the 
injection regimen began. 
Locomotor Activity 
Regardless of genotype, the first injection of METH increased motor activity as 
compared to saline treatment (Figure 4-1 B). In contrast, METH-treated mice exhibited 
less motor activity than saline-treated mice after the fourth injection (Figure 4-1 C). After 
the 14-day minocycline regimen (3 months of age), the motor activity of the METH 
treated mice was similar to that of saline-treated mice, regardless of genotype and 
minocycline treatment (Figure 4-1 D). 
Tyrosine hydroxylase immunohistochemistry 
Genotype effects 
Integrated density revealed that the TH-ir in the lateral striatum was similar 
between the different groups (Figure 4-2 A, E). However, in the medial region of the 
.. 
striatum, GDNF/- mice had lower TH-ir levels compared to age-matched WT mice 
(Figure 4-2 A, E, I). After a 14-day treatment regimen, GDNF/- mice treated with 
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minocycline displayed an increase in TH-ir in the medial striatum compared to saline-
treated GDNpl- mice (Figure 4-2 E, G, I). No effect of minocycline treatment was 
evident in WT mice. However, the TH-ir levels in minocycline-treated GDNF/- mice 
were still significantly lower than TH-ir levels seen in WT mice. 
Treatment effects 
METH treatment caused a greater reduction of TH-ir in the lateral striatum of 
GDNF/- (93%) than for WT (69%) mice two weeks after injections (Figure 4-2 C, D and 
E-Ieft). Similarly, METH produced a significantly greater decrease in TH-ir in the medial 
striatum of GDNF/- (89%) than in WT (55%) mice (Figure 4-2 C, D and E-right). When 
assessing the minocycline treatment effects on TH-ir, no differences existed between 
:METH treated mice, regardless of genotype (Figure 4-2). These data demonstrated that 
minocycline was not able to rescue the METH-induced striatal DAergic depletion, 
regardless of genotype, even though a significant TH-ir increase was seen in GDNF/-
mice treated with saline + minocycline. 
Substantia nigra microglial activation 
The microglial response in the striatum and SN to the toxic METH binge is 
illustrated in Figure 4-3. These cells were visualized with a CD45 antibody staining for 




At 3 months of age, saline-treated GDW'- mIce displayed more activated 
microglia in the SN than saline-treated WT mice (Figure 4-3 A, E, I). The two-week 
minocycline treatment reduced the amount of activated microglia in saline-treated 
GDW'- mice as evidenced by the morphological appearance and staining density 
observed in saline-treated WT mice (Figure 4-3 B, F, I), thus suggesting that GDNF 
minimizes inflammation that occurs in normal aging. 
Treatment effects 
As shown previously by other investigators (see Discussion), SN microglia were 
activated by METH (Figure 4-3 A, B, I), and the METH-induced microglial activation 
was greater for GDW'- than WT mice (Figure 4-3 G). METH-induced microglial 
activation was reduced in both WT and GDW'- mice following treatment with 
minocycline (Figure 4-3 D, H, I). However, the CD45 staining levels in lVlETH-treated 
mice were not reduced to those of saline-treated mice, regardless of genotype. These data 
indicate that inflammation does not significantly contribute to DAergic damage in the 
striatum of METH-treated mice, at least not in this model. 
Substantia nigra p38 MAPK phosphorylation 
Growing evidence indicates that phosphorylation of p38 MAPK is essential for 
the synthesis and release of pro-inflammatory mediators. In this study, we used a 
phospho-specific antibody to dete .. ct activation of p38 MAPK in the SN (Figure 4-4). 
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Genotype effects 
Three-month-old saline-treated GDNF/- mice demonstrated an increased intensity 
of phospho-p38 MAPK staining compared to age matched saline-treated WT mice 
(Figure 4-4 A, E, I). After undergoing a 14-day treatment regimen of minocycline, 
phospho-p38 MAPK signal intensity was attenuated in GDNF/- mice (Figure 4-4 E, H, 
I). 
Treatment effects 
Two weeks after a toxic binge of METH, phospho-p38 MAPK was increased in 
the SN, with the greatest increase seen in METH-treated GDNF'- mice (Figure 4-4 C, G, 
I). This increased activation was decreased in mice treated with minocycline, regardless 




In the present study, minocycline treatment attenuated the SN microglial 
activation and phospho-p38 MAPK response associated with a partial depletion of 
GDNF, as well as the increased microglial activation and p-38 MAPK seen with METH 
toxicity. Even though minocycline decreased the inflammatory responses, it had no 
effect on the METH-induced DAergic toxicity observed in the striatum, regardless of 
genotype. However, minocycline did increase TH-ir in GDNP'- mice compared to non-
minocycline treated GDW'- mice. 
Body Temperature 
Hyperthermia has been implicated in long-term DA depletions produced by the 
systemic administration of METH (Bowyer et aI., 1994; Albers and Sonsalla, 1995; 
Burrow et aI., 2000). Similar to the study presented in the previous chapter, the toxic 
METH binge resulted in a hyperthermic response that was similar between the two 
genotypes, suggesting that the same amounts of METH entered into the brains of WT ,and 
GDW'- mice. 
Locomotor Activity 
The nigrostriatal DA system plays an essential role in the control of voluntary 
movement (Chinta and Anderson, 2005; Ljungberg et aI., 1992). Similar to previous 
reports, in the present study, after the 1 st injection, METH-treated mice displayed more 
locomotor activity compared to saline-treated mice, regardless of genotype. This finding 
indicates an increased release of DA into the synapse from the terminal (Gold et aI., 
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1989; Yui et aI., 2004). Conversely, after the 4th injection, mice injected with METH 
displayed a decrease in locomotor activity, suggesting a depletion of DA stores in the 
terminal. The mice made a full recovery in locomotor activity, within 2 weeks of 
treatment suggesting that the system had adapted and recuperated behavioral performance 
even though DA levels remained low in the striatum of GDW'- mice treated with 
METH throughout the 12 months of study as seen in Chapter III. Minocycline treatment 
did not result in any alterations in locomotor performance. 
Tyrosine Hydroxylase Immunohistochemistry 
Minocycline treatment increased striatal TH-ir in young GDW'- mIce, 
suggesting that inflammation may play a role in the weak DAergic innervation of 
striatum associated with a long-term partial GDNF depletion reported in Chapter II and 
III of this dissertation. The restorative effect of minocycline in GDW'- mice could be 
due to the fact that minocycline completely reverses microglia-exacerbated injury to 
astrocytes (Yenari et aI., 2006). In the study conducted by Yenari and colleagues (2006), 
the addition of microglia to endothelial cell/astrocyte co-cultures increased cell death; 
however, the minocycline reduced the microglial-induced injury to the co-cultures. The 
astrocytic production/release of nel:1rotrophic factors such as GDNF, nerve growth factor, 
and neurotrophin-3 in the cultures, suggesting that minocycline may have neuroprotective 
properties (Mattson et aI., 1995; Duan et aI., 2001; Cunningham and Su, 2002). As 
mentioned previously, GDNF secretion from activated microglia has been proven to be 
beneficial in the recovery of locomotor activity after spinal cord injury, therefore 
providing neurotrophic support to GDNF-responsive neurons (Hashimoto et aI., 2005; 
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Appel et aI., 1997). However, future studies need to be conducted to determine if there is 
an increase in GDNF levels after minocycline treatment, thereby aiding in the restorative 
effects of minocycline. 
In contrast to the positive effects of minocycline on saline-treated GDW'- mice, 
the antibiotic was unable to restore the striatal TH loss associated with a toxic binge of 
METH. It is possible that minocycline did not prevent the METH-induced DAergic 
toxicity because minocycline was found to protect against experimental conditions 
known to promote caspase induction (Bantubungi et aI., 2005). In contrast METH results 
in spectrin proteolysis, which is mediated through calpain activation, and not through an 
increase in caspase activity, in a time-dependent manner within the striatum (Staszewski 
and Yamamoto, 2006). Spectrin is a cytoskeletal protein that contributes to neuronal 
integrity and proteolysis of this protein has been proposed as an important component of 
neuronal death (Lowy et aI., 1995). Furthermore, minocycline was not protective in a 
Huntington's disease model (3-nitropropionic) known to induce striatal neurotoxic 
damage via increased calpain activation, not caspase activation (Bantubungi et aI., 2005). 
Combined, these studies suggest that minocycline may not have had 
protective/restorative effects on striatal METH-induced toxicity in this study, because 
calpain, not caspase, was activated. Several studies have reported that there appears to be 
a lack of benefit or even detrimental effects of minocycline in neurodegenerative disease 
models depending on treatment strategy, dose, and timing of treatment (Smith et aI., 
2003; Yang et aI., 2003; Diguet et aI., 2003; 2004). Even more recently, Sriram and 
colleagues (2006) demonstrated a lack of protection of minocycline on the neurotoxicity 
induced by MPTP and l\1ETH, which they suggest may likely be due to minocycline's 
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inability to abolish toxin-induced TNFalpha and its receptors expression. Differences 
among these studies include differences in minocycline doses and treatment paradigm. 
This group suggests that the differences in results were due to differences in minocycline 
doses. However, the dosage of minocycline (45mg/kg, i.p. for 14 days) used in this study 
was based on previous studies in our lab suggesting the protective effects of this dose in 
animal models of PD (Quintero et aI., 2006) and Alzheimer's disease (Hunter et aI., 
2004). The data presented in this chapter suggest that while TH loss related to a partial 
depletion of GDNF may be dependent on latent inflammation in the mouse, METH-
related toxic effects have additional biological mechanisms, which cannot be solely 
attributable to inflammation. 
Substantia Nigra Microglial Activation 
Microglial activation has been found to occur in association with various types of 
brain injury (Kato et aI., 2000), as well as with damage caused by neurotoxic chemicals 
often used to model disease (Jorgensen et aI., 1993; Scali et aI., 1999; Fiedorowicz et aI., 
2001) as well as with DAergic neurodegeneration associated with PD and in animal 
models PD (Francis et aI., 1995; Czlonkowska et aI., 1996; Langston et aI., 1999). 
Microglial activation was observed in the SN of 3-month-old GDNF/· mice but not in 
WT mice (Chapter III) in this and the previous study (Chapter III). Even though GDNF/· 
mice have increased microglial activation, they do not demonstrate a loss of SN DAergic 
neurons until 12 months of age (Chapter 2, 3), These data suggest that these mice may 
exhibit latent microglial activation at an early age and it is possible that this process 
eventually could give rise to a decrease in the number of TH-positive neurons later in life. 
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In the present study, minocycline decreased CD45 staining intensity in the SN of 
GDWI- mice to levels comparable to WT mice. These data suggest that a latent 
inflammatory response is an integral part of early pathological changes observed in 
GDWI- mice. Similarly, minocycline significantly reduced the levels of activated 
microglia in mice treated with 1vffiTH, regardless of genotype. However, CD45 staining 
intensity did not completely decrease to levels seen in non-METH treated mice. This 
finding is in accordance with a previous study assessing the protective effects of 
minocycline against 1vffiTH-induced toxicity (Sriram et aI., 2006). The data from that 
study demonstrated that a high dose of minocycline (100 mg/kg, s.c.) was unable to 
abolish the increase of TNFa mRNA induced by (20 mg/kg, s.c.). Sriram and colleagues 
(2006) postulated that the inability of minocycline to prevent the METH-induced 
DAergic damage is a result of minocycline's inablility to suppress the induction of tumor 
necrosis factor a (TNFa) and its receptor. Thus, the attenuation of microglial activation 
is insufficient to protect against :METH-induced striatal DAergic damage. In future 
experiments, levels of TNFa and other proinflammatory cytokines need to be assessed to 
determine their possible involvement in 1vffiTH-induced striatal damage. 
Substantia Nigra p38 MAPK Phosphorylation 
The p38 MAPK pathway is activated by a number of cellular stresses and has 
been implicated in neuronal cell death associated with axotomy and excitotoxicity 
(Glicksman et aI., 1998; Kawasaki et aI., 1997). Similarly, inhibition of p38 MAPK 
improves the survival of DA neurons both in culture and after neurotransplantation in a 
rat model of PD (Zawada et aI., 2001). Furthermore, phosphorylated p38 MAPK was 
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increased in the SN of naive young adult mice with a partial depletion of GDNF when 
compared to WT mice (Figure 4). Similarly, METH treatment resulted in a further 
increase in staining for phospho-p38 MAPK in the SN. These findings coincide with the 
increased microglial activation observed in these mice, suggesting a possible role of the 
p38 MAPK pathway in genetic and neurotoxin-induced neuroinflammation, or at least 
that this pathway is altered by METH toxicity. 
The p38 MAPK pathway is thought to mediate inflammatory responses In a 
variety of cell types (Lee et aI., 1994; Chen and Wang, 1999), including microglia (Bhat 
et aI., 1998). Possibly by activating transcription factors that regulate the induction of 
inflammatory genes (Bhat et aI., 1998), the blockade of p38 MAPK can be expected to 
benefit neuronal populations affected by microglial activation and inflammation. 
Minocycline may exert protective effects in different ways. Many prior reports attribute 
the protective effects to reducing the phosphorylation ofp38 MAPK (Du et aI., 2001; Wu 
et aI., 2002; Hunter et aI., 2004). Because minocycline decreased phospho-p38 MAPK 
staining in GDNpl- mice, as well as mice of both genotypes exposed to a toxic binge of 
METH, butTH-ir was not affected, phopho-p38 MAPK appears not to be involved in 
METH-induced TH-ir depletion. 
In conclusion, the present study demonstrated minocycline can suppress 
microglial activation by decreasing the phosphorylated state of p38 MAPK in the SN of 
GDWI- mice and mice administered a toxic regimen of METH. Additionally, the anti-
inflammatory effects exerted by minocycline partially rescued DAergic damage reSUlting 
from a partial GDNF depletion; however, the anti-inflammatory effects of minocycline 
were not sufficient to prevent the DAergic terminals from METH-induced toxicity. 
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Thus, while TH expression in GDNF/- mice can be enhanced by minocycline, the toxic 
effects of METH on DA neurons are not reversed and therefore may depend on other 




Figure 4·1. METH-induced hyperthermia and locomotor activity did not differ 
between GDNF+1- and WT mice. (A) METH injections resulted in a significant increase 
of body temperature when compared to saline treated mice (p<O.05). However, GDW'-
mice did not differ in the hyperthermic response to :METH when compared to WT mice. 
(B) After the 1 st METH injection, regardless of genotype, the mice were hyperactive 
compared to saline treated mice (p<O.05). However, after the 4th injection (C) the mice 
treated with :METH, regardless of genotype, were hypoactive when compared to saline 
treated mice (p<O.05). Two weeks post :METH binge (D), after the 14 day minocycline 
regImen, no differences existed in locomotor activity between the groups (N=8). 
(*p=O.05). 
Figure 4·2. METH-induced striatal TH depletion is unaffected by minocycline 
(mino). Striatal TH-ir from WT and GDW'- mice treated with Sal + Sal (A, E), :METH 
+ Sal (B, F), Sal + Mino (C, G), and METH + Mino (D, H). No differences existed in the 
lateral region of the striatum between the GDW'- and WT mice treated with saline. (I) 
Quantification of the average integrated density of striatal TH-ir between the different 
treatment groups. In the medial region, the GDNF+/- mice displayed less TH-ir. Two 
weeks after the :METH binge, METH-induced a similar TH-ir depletion in the lateral 
striatum of GDW'- and WT mice (C, D) when compared to saline treated mice 
(p<O.OO 1) and a significantly greater depletion in the medial striatum of GDWI- than 
WT mice (p<O.Ol). Minocycline..treatment increased the TH-ir in the medial striatum of 
saline-treated GDW'- mice compared to non-minocycline treated GDWI-mice 
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(p<O.05). However, minocycline did not have any effect on :METH-treated mIce, 
regardless of genotype. (*p=O.05, **p=O.Ol, ***p=O.OOl). 
Figure 4-3. Minocycline attenuated the METH-induced microglial activation in the 
SN of GDNF+1- and WT mice. CD45 immunohistochemistry illustrating activated 
microglia in the SN of WT mice and GDNF/-mice treated with Sal + Sal (A, E), METH 
+ Sal (B, F), Sal + Mino (C, G), and METH + Mino (D, H). (I) Quantification of the 
average integrated density of CD45 immunoreactivity in the SN. Saline-treated GDNF/-
mice had more activated microglia in the SN when compared to saline-treated WT mice 
(p<O.Ol). J\,ffiTH induced more activated microglia in WT mice than saline (p<O.05). 
However, :METH treatment caused a significantly greater increase in microglial 
activation in the SN of GDNF/-mice two weeks after injection than saline. This increase 
was greater in GDNF+/- mice or METH-treated WT mice (p<O.Ol). Minocycline 
treatment reduced microglial activation in saline-treated GDNF/- mice to levels 
comparable to saline-treated WT mice. Also, minocycline attenuated the microglial 
activation in mice treated previously with METH, although not to levels comparable to 
saline-treated mice. N=8 per group (*p=O.05, **p=O.Ol). 
Figure 4-4. Phosphorylated p38 MAPK in the SN is decreased after minocycline 
treatment. Photomicrograph of p38 MAPK phosphorylation in the midbrain of WT and 
GDNF/-mice treated with Sal + Sal (A, E), METH + Sal (B, F), Sal + Mino (C, G), and 
METH + Mino (D, H). (I) Quantification of the average integrated density of phospho-
p38 MAPK immunoreactivity in the SN. Saline-treated GDWI- mice demonstrated 
115 
more phospho-p38 MAPK than saline-treated WT mice. METH treatment increased 
phosphorylation of p38 MAPK, with the greatest increase seen in METH-treated 
GDWI- mice (B, F). Minocycline decreased the levels of phospho-p38 MAPK in the SN 
of saline-treated GDNpl- mice. Furthennore, minocycline reduced the METH-induced 
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The previous chapters characterized a model of slow, progressive SN DAergic 
degeneration, a model for the "dual-hit" hypothesis of neurodegeneration, as well as the 
lack of neuroprotective effects of minocycline for :rvtETH-induced DAergic damage. The 
goal of this chapter is to discuss the broad implications these findings have for the 
potential role of GDNF and METH in PD-like pathologies and the implications for 
minocycline as a possible treatment for PD-like pathologies. The data presented in this 
dissertation suggest that further examination of combinatory effects of intrinsic and 
extrinsic factors in the onset of PD are warranted, and further that the GDW'- mouse 
may be suitable for such studies. 
The "dual-hit" hypothesis of neurodegeneration 
The idea of a "dual-hit" is of growing interest in the field of degenerative 
diseases. The first report of such a hypothesis was presented by Dr. Alfred George 
Knudson, Jr. when in 1971 he proposed a "two-hit" hypothesis for tumourogenesis 
(Knudson, 1971). Since then, the expression of many disorders has been proposed to 
depend on genetics and environmental factors, such as schizophrenia (Maynard et aI., 
2001) and PD (Gu et aI., 1998). 
It has been argued that the etiology of PD may be genetic or environmental, even 
though hardcore evidence for either or both is yet to be presented (Steece-Collier et aI., 
2002). Thus, it has been suggested that one or the other may be involved as a 
predisposition, upon which the other is superimposed, to induce severe DAergic cell loss 
in the SN (Gu et aI., 1998; Olanow and Tatton, 1999; Kidd, 2000). For example, a 
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genetic or environmental insult could induce cell loss and Lewy body formation in the 
SN. The profound cell loss in the SNpc is then induced by an additional, but alternative 
cause, either genetic or environmental (endogenous or exogenous), to produce the clinical 
features of PD. This hypothesis would suggest that some individuals may be exposed to 
only one of the two "hits" and, therefore, not develop PD, but would remain vulnerable to 
insults throughout their lifespan, similar to what has been discovered for schizophrenia 
(Maynard et aI., 2001). Thus 'one-hit' brains would show, at one end of the spectrum, 
either mild but diffuse neuronal cell loss with Lewy body fonnation or, at the other 
extreme, selective nigral cell loss (Gu et aI., 1998). 
Today, "dual-hit" hypotheses have been tested in animal models of stroke (Tomac 
et aI., 2000) and PD (Gao et aI., 2003) even though a systematic examination of these 
hypotheses has not been undertaken. When assessing the effects of focal cerebral 
ischemia, mice with a partial deletion of the GDNF receptor, GFRa-l, proved to be more 
vulnerable to the stroke injuries than WT mice (Tomac et aI., 2000; Sarabi et aI., 2003), 
thus suggesting that these mice were genetically predisposed to the toxic effects of the 
external insult In a study using a chronic in vitro model of PD, Gao and colleagues 
(2003) demonstrated that the herbicide, rotenone, and the endotoxin, lipopolysaccharide 
(LPS), worked in synergy to produce DAergic toxicity. The individual drug doses used 
in that study were nontoxic or minimally toxic; therefore alone they produced little or 
minimal neurotoxicity. However, when combined at the same concentrations, the two 
resulted in a synergistic DAergic neurotoxicity (Gao et aI., 2003). These data suggest 
that exposure to environmental {oxins and episodes of neufoinflammation, occuning 
either together or in tandem, may promote or trigger neurodegeneration. Furthermore, 
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the data presented in Chapters II and III of this dissertation suggest that mice with a 
partial depletion of GDNF are more susceptible to the deleterious effects of METH, 
supporting a dual-hit hypothesis when using these injury paradigms. 
Genetic Predisposition 
Which possible genetic alterations could constitute a genetic predisposition for 
Parkinson's disease? Several genes have been linked to the occurence of PD, including 
a-synuclein, parkin, ubiquitin-carboxy-terminal hydrolase L1 (UCHL1), and GDNF. 
Even though the normal physiological role of a-synuclein, a predominantly presynaptic 
protein, is unknown, it is presumed to aid in dopamine transporter activity. Mutations in 
the a-synuclein gene have been linked to a rare autosomal dominant form of PD 
(Polymeropoulos et aI., 1997). Also, a-synuclein protein has been found to accumulate 
in Lewy bodies (Spillantini et al. 1997), not only in patients with a-synuclein mutations 
but also in patients with sporadic PD. Studies have demonstrated that overexpression of 
a-synuclein resulted in apoptosis of DAergic neurons but not in non-DAergic human 
cortical neurons (Xu et aI., 2002). Of interest to note is that a-synuclein mRNA 
expression was upregulated in 12-month-old GD~/- mice in our preliminary study 
(Boger et aI., 2004). However, future studies need to be conducted to explore whether 
these mice actually form Lewy bodies. 
Mutations in the parkin gene are most common in the juvenile fonn of PD, with 
onset before the age of 40, although the onset of some rare cases is as late as the 60s 
(Klein et aI., 2000). Parkin is .. expressed in neurons as well as glial cells and blood 
vessels (Zarate-Langunes et aI., 2001) and is a component of the ubiquitin protein 
degredation system (Mizuno et aI., 2001). Therefore, mutations in this gene suggest the 
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importance of ubiquitin-mediated proteolysis in the pathobiology of PD (Giasson and 
Lee, 2001). UCHL1 is a highly abundant, neuronal specific protein that belongs to a 
family of de-ubiquitinating enzymes responsible for hydrolyzing polymeric ubiquitin 
chains to free ubiquitin monomers (Wilkinson et aI., 1989). UCHL1 has been localized 
to Lewy bodies in sporadic PD (Lowe et aI., 1990) and mutations result in loss of 
function have also been linked to PD (Leroy et at, 1998). Thus, both the ubiquitin ligase 
and hydrolase activities of UClll.J may play a role in the normal function of the 
ubiquitin-proteasome system and may be relevant to the pathogenesis of PD. 
In post-mortem studies, GDNF was decreased not only in the SN as a whole but 
within individual dopamine neurons of PD patients (Jenner and Olanow, 1998; Chauhan 
et aI., 2001). These clinical studies suggest a role for GDNF in the loss of SN dopamine 
neurons observed in PD patients, and we therefore chose to assess the effects of a partial 
GDNF depletion throughout the lifespan of male GDNF/- mice (Chapter 2). These 
studies showed that GDNF/- mice demonstrated a decline in locomotor activity as well 
as decreased performance on the accelerating rotarod with increasing age compared to 
WT littermates. Even though WT mice displayed an age-related reduction of 
spontaneous locomotion observed in the present study, which is similar to what has been 
reported for this mouse strain (C57B1I6J) in previous publications (Dean et aI., 1981), 
GDNF'- mice exhibited a greater age-related rate of motor decline than WT mice in the 
present study. Their activity declined several months earlier than that of WT mice. The 
data suggest that GDNF is involved in the regulation of spontaneous motor function 
andlor motor coordination, either via one or several transmitter systems, and that this 
influence becomes more pronounced with age. The present model may represent an 
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interesting model for motor dysfunction in animals, as the motor deficit developed much 
slower than that seen in the lesion models of PD (Cass et aI., 2005; Tamas et aI., 2005; 
Deumens et aI., 2001), and can thus be used for prevention or rescue studies that extend 
over several months, thus mimicking the situation in humans more closely. 
DAergic pathways are especially susceptible to the effects of normal agIng 
(McGeer et aI., 1977; Severson et aI., 1988; Carlsson 1987; Seeman et aI., 1987; Kish et 
aI., 1992). The loss of DA neurons found in the aged human brain is comparable to 
findings in animal models of aging. For example, Cass and collaborators (2002) reported 
a marked increase in the response to neurotoxins in aged SN DA neurons, and DA 
receptor binding (D2 receptors) is decreased in the brain of aged mice (Ossowska et at, 
2001). Other investigators have found a significant decline in both TH and DAT in the 
SN region of aged rodents (Himi et aI., 1995). These decreases in DA markers in the aged 
rodent brain are associated with a conspicuous decrease in spontaneous locomotion 
(Watanabe et aI., 1991; Hebert and Gerhardt, 1997). As described in Chapter 3, young 
adult (3 month old) untreated GDW/- mice have less TH-ir innervation in the medial 
striatum compared to age-matched WT mice. In contrast, GDWI- mice have greater 
striatal DA and DOPAC concentrations and increased DAT activity but no increase in the 
striatal DAIDOP AC ratio or in TH-ir cell number in the substantia nigra. This 
combination of results is suggestive of increased DA uptake and DA accumulation in the 
surviving axons without increased synthesis or turnover. 
In mid-life (12 months), the medial striatum of GDWI- mice contained less TH-
ir per area, and both striatal areas .. had less TH-ir mean density and less DA and DOPAC, 
a combination suggesting that DA uptake is unable to compensate for reduced synthesis 
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later in life. In the substantia nigra, GDWI- mice were distinguishable from WT mice 
with a greater overall decline (35.7%) of nigra! TH-positive neurons which occurred 
earlier in the life span, between 8 and 12 months of age rather 20 months as seen in WT 
mIce. These data confirm the idea that GDNF plays an important role in the 
maintenance, survival, and function of the nigrostriatal dopamine system during aging. 
This slow, progressive loss is consistent with PD pathology; unlike the rapid loss that 
occurs in most 6-0HDA and MPTP lesion models (Faull and Laverty, 1969; Cass et aI., 
1996; Orth and Tabrizi, 2003). 
However, other animal models exist which model a slow, progressive loss of SN 
DA neurons coupled with motor impairment. One of these models consists of mice 
overexpressing human doubly mutated <l-synuclein (A53T and A30P, line hm2a-SYN-
39), two mutations common in PD (Thiruchelvam et aI., 2004). The authors were able to 
demonstrate that the hm2a-SYN-39 mice displayed an age-related decline in motor 
activity, starting at 16 months of age. The motor performance decline observed in hm2a-
SYN-39 mice was associated with a decrease inTH-positive SN neurons with age 
(Thiruchelvam et aI., 2004). Thus, suggesting that mice overexpressing mutated forms of 
human a-synuclein mimic PD-like pathologies. More recently, studies have proposed the 
idea that rodents prenatally exposed to neurotoxins may have increased DAergic damage 
during aging. One such model is the prenatal lipopolysaccharide (LPS) animal model of 
PD (Ling et aI., 2002; 2006). Pregnant rats were injected with LPS at gestational day 
10.5, the critical time in which DA neurons develop_ When the animals were born, they 
displayed fewer than normal DA~ neurons (Ling et aI., 2002). This DA neuronal loss is 
pennanent since the loss is still present in 16-month-old rats, the oldest age studied to 
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date (Carvey 'et aI., 2003). These data suggest that exposure to LPS in utero, which 
occurs during pregnancy complicated by bacterial vaginosis, serves as a risk factor for 
PD (Ling et aI., 2002). These three models (GDNF'- mice, hm2a-SYN-39, and prenatal 
LPS exposure) resemble the slow, progressive impairments of the DA system and motor 
performance associated with PD. 
What are the biological mechanisms for the delayed TH-ir cell loss in GDNF'-
mice? There is considerable evidence from the literature that the underlying mechanisms 
of selective DA neuronal vulnerability consist of 1) mitochondrial dysfunction, 2) 
inflammatory processes, 3) oxidative stress, and 4) proteolytic stress (Moore et aI., 2005; 
Ogawa et aI., 2005). Collectively, mitochondrial dysfunction, inflammatory processes, 
and oxidative stress are all related to the progression of DA neuronal death. However, 
impairment of the ubiquitin-proteasome system (UPS) and the unfolding and aggregation 
of cytotoxic proteins are associated with PD pathology and may therefore indirectly be 
involved (Giasson and Lee, 2003; Moore et aI., 2003). Studies have shown that 
inhibition of proteasome activity results in the formation of ubiquitinla-synuclein-
positive inclusions both in vivo (Fomai et aI., 2003; NcNaught et aI., 2002a) and in vitro 
(McNaught et aI., 2002b). In the striatum of 12-month-old GDNF'- mice, the mRNA of 
a-synuclein was upregulated in comparison to age-matched WT mice. These data 
suggest the possibility that GDNF'- mice have impairments in the UPS system, resulting 
in increased a-synuclein expression. Future studies will consist of confirming the protein 
expression of a-synuclein in these mice and tracking the expression throughout life. 
Furthermore, it is not yet confirriled whether Lewy bodies form in GDNP'- mice during 
aging, it has been demonstrated that Lewy body formation can occur in rodents (Paul 
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Carvey, personal communication), so it would be an exciting finding. It would be of 
interesting to conduct future studies to assess each of these mechanisms in mice with a 
partial depletion of GDNF to determine the underlying cause(s) of accelerated DAergic 
cell loss associated with aging, including oxidative stress. 
Collectively, the GDNF heterozygous mouse has fairly subtle alterations in motor 
function and DA morphology as aging progresses, and most alterations are evident also in 
the WT mice but at later ages. Genetic neurotrophin depletion may cause increased DA 
neuronal vulnerability when individuals are presented with a neurotoxin, demonstrating 
that a combination of intrinsic and extrinsic factors can increase age-related vulnerability 
of midbrain DA neurons. These data provide evidence for a role of GDNF in the 
maintenance of the nigrostriatal DAergic system, and also provide a novel animal model 
for therapeutic intervention, both in terms of prevention and rescue, of aging DA neurons. 
Genetic Predisposition coupled with an environmental toxin 
In 1983, CaIne and Langston, suggested that PD is a result of the combined 
effects of genetic and environmental factors. Based on this and other epidemiological 
studies (CaIne and Langston, 1983; Semchuk et aI., 1993; Tanner and Goldman, 1996; 
Reiss and Kruger, 1999), animal studies have been conducted to assess this "dual-hit" 
hypothesis (see ego Gu et aI., 1998; Gao et aI., 2003). The focus of Chapter III of this 
dissertation is on a genetically altered animal model (GDNF/- mice) combined with long-
term response to an environmental neurotoxic insult (METH). 
In this study, motor activity deficits resulting from :METH treatment did not occur 
until mice, regardless of genotype, reached 9 months of age. Further, it wasn't until 12 
129 
months of age that GDNF/- mice displayed less activity than WT mice, whether they 
were previously treated with METH or not. This result confirms that data presented in 
Chapter II, in which a reduction of motor activity in GDNF/- mice was first detected at 
12 months of age. The data in Chapter III indicate that the decline 'in motor activity 
associated with aging was greater for METH-exposed GDNF'- than WT mice, 
supporting the dual-hit hypothesis. Thus, it is reasonable to speculate that young adults 
who binge on high doses of METH may experience deleterious motor consequences as 
they age. 
In Chapter ITI, when comparing GDNF/-mice to WT mice, GDW'- mice treated 
with METH displayed greater detrimental DAergic effects at 3 and 12 months of age. 
The clearest example is the more profound METH-induced depletion of TH-ir in 
GDW'- mice than in WT mice. This greater decrease in TH-ir was coupled with a 
greater loss of striatal DA and DOPAC after METH administration in GDNF+1- mice, 
suggesting a greater decrease in DA synthesis in these mice. At 12 months of age, middle 
age for mice, recovery was evident in all the measures mentioned above, however, the 
GDWI- mice treated with METH still had a significant decrease in TH-ir, DA, and 
DOPAC when compared to WT mice again suggesting less DA synthesis for the METH-
treated GDNF/- mice. At 12 months of age, 5-HT levels in the striatum were lower in 
METH compared to saline treated mice, an effect that was enhanced in GDWI- mice, 
suggesting a possible role for GDNF in serotonergic innervation later in life. Recently, 
researchers demonstrated that GDNF treatment (100nglml) for five days significantly 
increased serotonergic cell densities in ventral mesencephalic cultures (Ducray et al., 
2006). Similarly, the addition of GDNF increased serotonergic soma size, the number of 
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primary neuritis/neuron, and the neurite length/neuron (Ducray et aI., 2006). These 
effects of GDNF on serotonin neurons are modest in comparison to GDNF effects of DA 
neurons. The direct effects of GDNF on 5-HT neurons could possibly be due to the 
presence of its receptor, GFRa-l, on serotonergic neurons of the raphe nucleus (Sarabi et 
aI., 2003). Therefore, it is possible that the reduction of GDNF could have adverse 
effects on the serotonergic system. Furthermore, alterations in the serotonergic system 
have been detected in PD; however, the exact role of 5-HT in PD pathology is unknown 
(Scholtissen et aI., 2006). In addition to deficits in the DA and 5-HT systems, decreased 
function of the locus coeruleus noradrenergic (LC-NE) neurons has been found during 
normal aging and in neurodegenerative disorders (Soldani and Fomai, 1999). Similarly, 
aged GDNF/- mice demonstrated reductions in NE transporter activity in the cerebellum 
and brain stem as well as decreased NE tissue levels in the LC (Zaman et aI., 2003). TH 
immunostaining demonstrated morphological alterations of LC-NE cell bodies and 
abnormal TH-positive fibers in the hippocampus, cerebellum, and frontal cortex of 
GDNF/- mice. These findings suggest that the LC-NE system of GDNF'- mice is 
impaired and suggest that GDNF plays an important role in continued maintenance of 
this neuronal system throughout life (Zaman et aI., 2003). Collectively, these data 
suggest that GDNF+1- mice are more vulnerable to the neurotoxic effects of catecholamine 
toxins. 
It is important to note that in spite of an 88% reduction in striatal tissue DA levels 
noted for GDNpl- mice treated with METH at 3 months of age (2 weeks post-injection), 
no loss of TH-positive neurons in .. the substantia nigra or motor acti vity impairments were 
noted under the conditions of this experiment. In support of these findings, Robertson 
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and colleagues have suggested that a number of compensatory neuroadaptions occur in 
DA systems in response to neuronal damage (Robertson and Robertson, 1988; Hoffer et 
aI., 1994; Hoffman and Gerhardt, 1999). They denionstrated that following a toxic insult, 
SN dendritic release may take over, thereby increasing extracellular DA levels and 
resulting in recovery of locomotor function (Robertson and Robertson, 1988). Another 
possible reason for the absence of motor deficits in the 3 month old mice is that DA 
innervation of the nucleus accumbens, a related brain structure that mediates locomotor 
activity (Swanson and Kalivas, 2000, Swanson et aI., 1997), was unaffected by the 
treatment suggesting that this brain region is involved in adaptive responses in younger 
but not older GDWI- mice. 
Experiments were conducted to determine the biological mechanism for the 
hightened response to :METH in GDWI- mice. METH-induced hyperthermia and 
striatal METH concentrations did not differ between genotypes; therefore these 
parameters could not contribute to the exacerbation in DA toxicity of GDWI- mice. 
Alternatively, DAT activity, which is critically involved in the inward transport of :METH 
with simultaneous outward transport of DA (Liang and Rutledge, 1982), is an important 
determinant of METH neurotoxicity and a likely candidate for the drug's enhanced 
neurotoxicity observed for GDWI- mice. METH-induced reductions in striatal DA 
parameters are blocked by DAT antagonists (Schmidt and Gibb, 1985; Marek et al., 
1990; Pu et aI., 1994). This protective action can occur even if the DAT inhibitor is 
administered as long as 8 hrs after the neurotoxic METH treatment (Marek et al., 1990). 
The critical role of DAT in METJI neurotoxicity is further supported by the observation 
of Caron and coworkers that METH toxicity is completely absent in DAT knockout mice 
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(Fumagalli et aI., 1998). In the present study, mice with a partial depletion of GDNF 
displayed higher DAT activity, but not protein, at 3 months of age. This increase in 
activity might suggest that the GDNpl- mice were able to take up more METH into 
striatal DAergic terminals resulting in increased DA neural toxicity. 
Another biological mechanism for the increased DAergic toxicity in GDW'-
mice could be neuroinflammation. Inflammation has also been implicated in METH-
induced toxicity (Lavoie et aI., 2004; Thomas et al., 2004a; 2004b). In Chapter III, it was 
demonstrated that GDNF+1- mice displayed increased microglial activation in the SN at 3 
months of age, an effect that was further increased with METR treatment. These data 
suggested that a latent inflammatory response may be present in young GDW'- mice 
which would then exacerbate DAergic toxicity following METR. Future studies will be 
conducted to assess other biological mechanisms which may be involved in the increased 
METH-induced DAergic toxicity seen in mice with a partial depletion of GDNF, such as 
oxidative stress, dysregulation of apoptotic pathways, and glutamate excitotoxicity 
(Cadet and Brannock 1998; Hirata et al. 1997, 1996; Imam and Ali 2001; Jayanthi et al. 
2004; Sonsalla et aI., 1986, 1991; Mark et aI., 2004). 
Taken together, the data from Chapters II and III suggest that a life-long reduction 
of GDNF or exposure to toxic doses of METH during young adulthood lead to long-term, 
but fairly subtle, alterations in the nigrostriatal DAergic system. However, in 
combination, the two factors cause exacerbation of DAergic damage, thus confirming a 
"dual-hit" hypothesis of neurodegeneration, which postulates that a combination of 
factors during early pre- and p(()stnatal development or young adult life gives rise to 
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enhanced vulnerability of the DA neurons and leads to altered neuronal functioning, 
during aging. 
Anti-inflammatory Treatment in Dual-Hit Mice 
Activation of the p38 MAPK pathway has been implicated in the pathology of 
several neurodegenerative diseases, including Alzheimer's disease and Parkinson's 
disease (Perry et aI., 1999; Ferrer et aI., 2001a; 2001b). Similarly, in vivo studies have 
also demonstrated increased p38 MAPK phosphorylation in animal models of 
neurodegeneration (Yrjanheikki et aI., 1998; 1999; Lin et aI., 2001; Kriz et aI., 2002; Du 
et aI., 2001; Wu et aI., 2002). Data presented in this dissertation demonstrate that a 
lifetime reduction in GDNF results in an increase of microglial activation and an increase 
in phospho-p38 MAPK in the SN (Chapter IV). Thus, it is possible that the increase in 
phospo-p38 MAPK could contribute to the DA cell loss observed in these mice at 12 
months of age (Chapter II), something which was indicated by the effects of minocycline 
on TH levels in Chapter IV but has to be proven further. Similarly, a toxic regimen of 
:METH induced an increase in phospho-p38 MAPK in the SN (Chapter IV). 
The powerful anti-inflammatory properties of minocycline have been 
demonstrated both in vivo and in vitro, by inhibiting microglial activation and a reduction 
in the phosphorylation of p38 MAPK (Yrjanheikki et aI., 1998; 1999; Lin et aI., 2001; 
Kriz et aI., 2002; Du et aI., 2001; Wu et aI., 2002; Tikka et aI., 2001a; 2001b). Data 
presented in Chapter IV demonstrated that minocycline reduced the microglial activation 
and decreased phospho-p38 MAPK in GDNpl- mice and METH-treated mice. In 
addition to the attenuation of the inflammatory response, minocycline treatment partially 
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restored TH-ir in the striatum of GDNF/- mice, therefore suggesting that the p38 MAPK 
pathway is possibly involved in the degeneration associated with a partial loss of GDNF. 
In contrast, minocycline was unable to rescue the DAergic damage associated with 
METH toxicity, thus suggesting that inflammation and the activation of the p38 MAPK is 
only partially, or not involved at all, in the damage caused by METH. 
There are several other possible mechanisms associated with the toxic effects of 
METH, including mitochondrial dysfunction, oxidative stress, and glutamate 
excitotoxicity. Methamphetamine has been shown to alter mitochondrial function by 
increasing the pH of the inner matrix, reducing ATP-synthase activity, thereby reducing 
the capacity to maintain membrane potential (Davidson et aI., 2001). 1v.IETH causes an 
increase of mitochondrial-derived ROS, but inactivating the vesicle proton pump, 
resulting in released DA and increase formation of DA-quinones which open the 
permeability transition pore of the mitochondria allowing for increased release of Ca2+ 
and the induction of caspase cascades (Davidson et aI., 2001).. Alternatively, GDNF 
treatment has been shown to decrease mitochondrial dysfunction by decreasing oxidative 
stress, H202 production, increasing intracellular glutathione levels and increasing survival 
promoting cell signaling in response to a toxic insult of 3-nitropropionic acid and in 
cytoplasmic hybrid cells from mitochondrial DNA of idiopathic PD which contains 
reduced levels of glutathione and increased vulnerability to H202 (Onyango et aI., 2005; 
Araujo et aI., 1998). Based on this information, it is possible that a reduction in GDNF 
levels could increase the susceptibility of DA neurons to oxidative stress in response to 
mitochondrial dysfunction. 
135 
Furthermore, glutamate excitotoxicity has been linked to the DAergic damage 
observed in the striatum of METR-treated mice (Mark et aI., 2004; Carlsson and 
Carlsson, 1990) because increased activity in the striatonigral pathway leads to an 
increase in corticostriatal glutamate release. The increase in striatal glutamate release 
possible activated AMPA receptors on the DA terminals to increase the influx of Ca2+, 
thus resulting in calpain-mediated spectrin proteolysis (Staszewski and Yamamoto, 
2006). Furthermore, the activation of calpain has been shown to inhibit the ability of 
cytochrome c to activate caspase cascades in hippocampal cultures exposed to N:MDA, a 
model of excitotoxicity (Lankiewicz et aI., 2000). More recently, GDNF administration 
has been demonstrated to decrease glutamate excitotoxicity in cultured hippocampal 
neurons (Wong et aI., 2005). Therefore, it is possible that reducing the levels of GDNF 
decreases a neuron's capacity to protect against glutamate-induced toxicity over time. 
Future studies will be conducted to assess oxidative stress and glutamate-related toxicity 
in both models presented here to determine if a combined treatment of minocycline with 
an anti-oxidant, such as vitamin E or blueberry extract, or a drug that would increase the 
glutamate transporter expression to increase the clearance of glutamate from the synapse, 
such as ceftriaxone, a ~-lactam antibiotic (Rothstein et aI., 2005), would be effective. In 
a preliminary study, pretreatment with ceftriaxone prevented the DAergic damage 
associated with a toxic binge of METR. In addition to its protective effects, ceftriaxone 
administration was accompanied by an increase expression of glutamate transporter 
(GLT -1) in the striatum (Vuthiganon et aI., 2005). These data suggest that ceftriaxone 
provides protection against METH neurotoxicity, possibly by increasing glutamate 
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uptake. Therefore, it is of interest to determine if ceftriaxone would restore the striatal 
DAergic damage in GDW'- mice in response to METH toxicity. 
Modeling DAergic loss: importance and future directions 
The nigrostriatal dopamine system is a major target of the pathogenesis of 
Parkinson's disease (Anden et aI., 1966; Krueger et aI., 1976; Bernier et aI., 1982). It is 
of interest to note, that no animal models exist that mimic all of the pathologies 
associated with PD. Such a model would include progressive SN DA neuronal 
degeneration, a-synuclein inclusions, Lewy body formation, inflammatory markers, and 
motor dysfunction accompanied by mitochondrial dysfunction and oxidative stress. For 
instance, MPTP and 6-0HDA lesions are the most common models for the assessment of 
PD; however, these models induce a rapid reduction in the nigrostriatal dopamine system. 
It is difficult to determine how and why SN DA neurons degenerate in PD without a 
model that demonstrates a slow, progressive decline. Mice with a partial depletion of 
GDNF could prove to be such a model. In our attempt to characterize PD-like 
pathologies, we have noted a progressive motor decline (Chapters II and III), a 
progressive loss of SN DA neurons (Chapters II and III), age-related decline in striatal 
DA and DOP AC levels (Chapter II), increased a-synuclein and D2 receptor mRNA 
expression (Chapter II), increased activation of microglia (Chapters III and IV), and 
increased vulnerability to environmental toxins (Chapters III and IV). However, future 
studies will be conducted to determine the exact mechanism(s) involved in the 
pathologies demonstrated in QDW'- mice, including mitochondrial dysfunction, 
oxidative stress, and impairment of the ubiquitin-proteasome system. 
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In 1983, CaIne and Langston, suggested that PD is a result of the combined 
effects of genetic and environmental factors. Data presented in this disseration suggest 
that mice with a partial depletion of GDNF demonstrate an increased vulnerability to the 
deleterious effects of an external toxin, METH. In combination, the two factors result in 
an exacerbation of DAergic damage, thus confirming a "dual-hit" hypothesis of 
neurodegeneration. Accordingly, this dual-hit model may provide face validity for the 
study of the abnormalities that underlie selective DAergic degeneration. In addition, this 
model may be useful for examining the effects of pharmacological treatment aimed at 
reducing DAergic loss or improving motor dysfunction. Future studies should be 
conducted to determine if minocycline treatment during young adulthood would prevent 
the DA loss in older GDNF/- mice. Similarly, studies should be conducted to determine 
if inflammation is the primary cause for the DAergic loss observed in GDNF'- mice, and 
if the damage observed in these mice after METH administration respresents a 
compilation of detrimental effects. In this manner, the dual-hit model can further our 




Figure 5-1. Alterations in DAergic markers and possible mechanisms at 3 and 12 
months of age in GDNF+/- mice treated with METR. At 3 months of age, GDWI-
mice have increased striatal DAT activity, resulting in increase DA and DOPAC tissue 
levels in the striatum. The increase in tissue DA could possibly lead to increase 
formation of DA-quinones, resulting in increase oxidative stress. At this age, GDNpl-
mice also display an increase in activated microglial and phospho-p38 MAPK in the 
substantia nigra, suggestive of increase inflammation. The increase in DAT activity 
suggests that more :METH was taken up into the DA terminal in GDWI- mice. This 
increase of METH uptake resulted in a greater decrease of TH-ir, and striatal DA and 
DOPAC levels when compared to METH-treated WT mice two weeks post-injection. In 
addition to the effects in the striatum, the administration resulted in a latent inflammatory 
response in the SN, which was evident with an increase in microglial activation and 
phospho-p38 MAPK staining. These data suggest an increased vulnerability of DA 
neurons in GDWI- to the neurotoxic effects of METH. However, other possible 
mechanisms exist including METH-induced mitochondrial dysfunction and increased 
formation of DA-quinones in response to the increased intracellular DA levels because of 
methamphetamine's ability to block VMAT-2 activity. When GDWI- mice are 12 
months of age, they display a decrease in striatal TH-ir, DA, and DOPAC levels, as well 
as a decrease in the number of SN DA neurons. However, at this age, the function of the 
DAT is unknown in these mice. Similarly, at this age, it is not known if there is an 
increase in oxidative stress of mitochondrial function. After METH treatment, recovery 
in DAergic damage is evident with time. When GDNF+1- mice were administered METH 
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at 2.5 months of age, they displayed more prolonged effects with lasting decreases in 
striatal TH-ir, DA, and DOPAC levels. Again these effects could be due to the ability of 
METH to increase mitochondrial dysfunction and oxidative stress. It is possible that the 
increased vulnerability of GDNF+/- mice is not strictly due to inflammation; therefore, 
however, future studies will be conducted to determine the role of oxidative stress and 
mitochondrial function in the increased deterioration of DAergic markers in GDNF'-
mlce. 
Figure 5-2. Possible. protective mechanism of minocycline treatment. The 
administration of minocycline resulted in a decrease of phospho-p38 MAPK and 
activated microglia. The inhibition of the p38 MAPK pathway resulted in the inhibition 
of lipid peroxidation from the formation of reactive oxygen species (ROS), protein 
nitration from the induction of nitric oxide (NO), and the inhibition of cytochrome c 
activation of caspase cascades. However, minocycline had no effect on METH-induced 
DAergic toxicity. This could possible be due to minocycline's inability to block caplain 
activation as a result of increase Ca2+ influx due to increased glutamate activation of 
AMPA receptors on the DAergic terminal. Also, it is possible that calpain activation 
results in the inhibition of caspase pathways, thus leading to necrosis/terminal 
degeneration. 
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